US20130203661A1 - Highly soluble leptins - Google Patents

Highly soluble leptins Download PDF

Info

Publication number
US20130203661A1
US20130203661A1 US13/852,521 US201313852521A US2013203661A1 US 20130203661 A1 US20130203661 A1 US 20130203661A1 US 201313852521 A US201313852521 A US 201313852521A US 2013203661 A1 US2013203661 A1 US 2013203661A1
Authority
US
United States
Prior art keywords
seq
leptin
amino acid
chimeric polypeptide
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/852,521
Other languages
English (en)
Inventor
Mary Erickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amryt Pharmaceuticals Inc
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Priority to US13/852,521 priority Critical patent/US20130203661A1/en
Publication of US20130203661A1 publication Critical patent/US20130203661A1/en
Assigned to AMYLIN PHARMACEUTICALS, INC. reassignment AMYLIN PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ERICKSON, MARY
Assigned to AEGERION PHARMACEUTICALS, INC. reassignment AEGERION PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMYLIN PHARMACEUTICALS, LLC, ASTRAZENECA PHARMACEUTICALS LP
Assigned to ASTRAZENECA PHARMACEUTICALS LP reassignment ASTRAZENECA PHARMACEUTICALS LP ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMYLIN PHARMACEUTICALS, LLC
Assigned to AMYLIN PHARMACEUTICALS, LLC reassignment AMYLIN PHARMACEUTICALS, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AMYLIN PHARMACEUTICALS, INC.
Priority to US14/703,523 priority patent/US10087228B2/en
Assigned to NOVELION THERAPEUTICS INC. reassignment NOVELION THERAPEUTICS INC. PATENT SECURITY AGREEMENT Assignors: AEGERION PHARMACEUTICALS, INC.
Assigned to AEGERION PHARMACEUTICALS, INC. reassignment AEGERION PHARMACEUTICALS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: NOVELION THERAPEUTICS INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Definitions

  • the invention provides novel compounds that have demonstrated biological activity.
  • the compounds also demonstrate surprising and significant improvement in physical properties, such as solubility and stability.
  • the compounds of the invention are based on leptin sequences disclosed in U.S. Application No. 61/387,402 and U.S. Application No. 61/422,091.
  • the compounds are surprisingly highly soluble and do not demonstrate the propensity to aggregate, unlike the naturally occurring leptins.
  • the physical properties of the compounds facilitate the preparation of soluble, pharmaceutically acceptable formulations and compositions, also provided by the invention.
  • Diseases amenable to such treatment include lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease, diabetes (including type I and type II), nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X, and Huntington's Disease, or combinations thereof.
  • chimeric polypeptide compounds having leptin biological activity, in addition to enhanced physical properties.
  • the compounds are chimeric polypeptides which are based on a wild type seal leptin polypeptide wherein at least one contiguous region of 1-30 amino acids of a wild type seal leptin sequence has been replaced with a contiguous region of 1-30 amino acids of a mature human leptin sequence.
  • a chimeric polypeptide as described herein in a first aspect, there is provided a chimeric polypeptide as described herein.
  • a method for treating a disease or disorder in a subject in need of treatment includes administering a chimeric polypeptide as described herein to the subject.
  • composition which includes a chimeric polypeptide described herein in combination with a pharmaceutically acceptable excipient.
  • polynucleotides encoding the chimeric polypeptide and their intermediates, expression vectors bearing such polynucleotides, host cells expressing such polynucleotides, and means for their expression, synthesis, post-translational modification and isolation.
  • FIGS. 1A-1C depict the effects of a daily administration of the indicated chimeric polypeptides described herein on food intake and change in body weight (% vehicle-corrected) upon administration to C57/B6 female mice as described in Example 4.
  • FIG. 1A food intake.
  • FIG. 1B change in body weight (% vehicle-corrected).
  • FIG. 1C dose response curve.
  • FIGS. 2A-2C depict the effects of a daily administration of the indicated chimeric polypeptides described herein on food intake and change in body weight (% vehicle-corrected) upon administration to C57/B6 female mice as described in Example 5.
  • FIG. 2A food intake.
  • FIG. 2B change in body weight (% vehicle-corrected).
  • FIG. 2C dose response curve.
  • “Obesity” and “overweight” refer to mammals having a weight greater than normally expected, and may be determined by, e.g., physical appearance, body mass index (BMI) as known in the art, waist-to-hip circumference ratios, skinfold thickness, waist circumference, and the like.
  • BMI body mass index
  • the Centers for Disease Control and Prevention (CDC) define overweight as an adult human having a BMI of 25 to 29.9; and define obese as an adult human having a BMI of 30 or higher. Additional metrics for the determination of obesity exist. For example, the CDC states that a person with a waist-to-hip ratio greater than 1.0 is overweight.
  • Lean body mass refers to the fat-free mass of the body, i.e., total body weight minus body fat weight is lean body mass. Lean body mass can be measured by methods such as hydrostatic weighing, computerized chambers, dual-energy X-ray absorptiometry, skin calipers, magnetic resonance imaging (MRI) and bioelectric impedance analysis (BIA) as known in the art.
  • MRI magnetic resonance imaging
  • BIOA bioelectric impedance analysis
  • “Mammal” refers to warm-blooded animals that generally have fur or hair, that give live birth to their progeny, and that feed their progeny with milk. Mammals include humans; companion animals (e.g., dogs, cats); farm animals (e.g., cows, horses, sheep, pigs, goats); wild animals; and the like.
  • the mammal is a female. In one embodiment, the mammal is a female human. In one embodiment, the mammal is a cat or dog.
  • the mammal is a diabetic mammal, e.g., a human having type 2 diabetes. In one embodiment, the mammal is an obese diabetic mammal, e.g., an obese mammal having type 2 diabetes.
  • the term “subject” in the context of methods described herein refers to a mammal.
  • “Fragment” in the context of polypeptides refers herein in the customary chemical sense to a portion of a polypeptide.
  • a fragment can result from N-terminal deletion or C-terminal deletion of one or more residues of a parent polypeptide, and/or a fragment can result from internal deletion of one or more residues of a parent polypeptide.
  • “Fragment” in the context of an antibody refers to a portion of an antibody which can be linked to a biologically active molecule to modulate solubility, distribution within a subject, and the like.
  • leptin A200 described herein is a conjugate of an Fc antibody fragment with a leptin, as known in the art. See e.g.
  • polypeptides refers, in the customary sense, to a polypeptide which serves as a reference structure prior to modification, e.g., insertion, deletion and/or substitution.
  • Analog as used herein in the context of polypeptides refers to a compound that has insertions, deletions and/or substitutions of amino acids relative to a parent compound.
  • An analog may have superior stability, solubility, efficacy, half-life, and the like.
  • an analog is a compound having at least 50%, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or even higher, sequence identity to the parent compound.
  • Identity refers to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 50% identity, preferably 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a sequence comparison algorithms as known in the art, for example BLAST or BLAST 2.0.
  • sequence comparison typically one sequence acts as a reference sequence, to which test sequences are compared.
  • sequence comparison algorithm test and reference sequences are entered into a computer, subsequent coordinates are designated if necessary, and sequence algorithm program parameters are designated.
  • sequence algorithm program parameters Preferably, default program parameters can be used, or alternative parameters can be designated.
  • sequence comparison algorithm calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
  • Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, 1981 , Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman & Wunsch, 1970 , J. Mol. Biol. 48:443, by the search for similarity method of Pearson & Lipman, 1988 , Proc. Nat'l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection.
  • BLAST and BLAST 2.0 are used, as known in the art, to determine percent sequence identity for the nucleic acids and proteins of the invention.
  • Software for performing BLAST analyses is publicly available through the web site of the National Center for Biotechnology Information.
  • This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence.
  • T is referred to as the neighborhood word score threshold (Altschul et al., Id.).
  • HSPs high scoring sequence pairs
  • a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
  • the BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.
  • Leptins Leptins. “Leptins” and “a leptin” means: leptins, leptin active fragments, leptin analogs, and leptin derivatives; and a leptin, a leptin active fragment, a leptin analog, and a leptin derivative; respectively. Accordingly, unless otherwise noted, reference to “leptins” is meant to encompass leptins, leptin active fragments, leptin analogs, and leptin derivatives, as disclosed herein.
  • a leptin is meant to encompass a leptin, a leptin active fragment, a leptin analog, and a leptin derivative, as disclosed herein.
  • exemplary leptins which may be employed in the design, preparation, and use of the chimeric polypeptides disclosed herein include those which elicit one or more biological responses known in the art to be elicited when leptins are administered to subjects (see, e.g., published U.S. Patent application Nos. US 2007/0020284 and US 2008/0207512, U.S. Pat. No. 6,309,853, and U.S. Pat. No. 7,183,254, and PCT Published Application Nos.
  • WO 96/005309, WO 98/28427, and WO 2009/064298 such as: reduction of food intake, reduction of body weight, reduction of body weight gain, induction of satiety, reduction of caloric availability, reduction of caloric efficiency, reduction of metabolic plateau, increase in insulin sensitivity, reduction of hyperlipidemia, correction of dyslipidemia, reduction of hypertriglyceridemia, amelioration of obesity, amelioration of overweight, amelioration of diabetes mellitus (including type I diabetes, type II diabetes, and gestational diabetes), amelioration of insulin resistance, amelioration of lipodystrophy conditions associated therewith, as well as other biological responses known in the art to be elicited upon administration of a leptin (see, e.g., published U.S.
  • Leptins include, but are not limited to, the compounds described in U.S. Pat. No. 5,594,101, U.S. Pat. No. 5,851,995, U.S. Pat. No. 5,691,309, U.S. Pat. No. 5,580,954, U.S. Pat. No. 5,554,727, U.S. Pat. No. 5,552,523, U.S. Pat. No. 5,559,208, U.S. Pat. No. 5,756,461, U.S. Pat. No. 6,309,853, published U.S. Patent application No. US 2007/0020284, and PCT Published Application Nos.
  • leptins Representative leptins, leptin analogs, leptin active fragments, and leptin derivatives include the following:
  • Unprocessed Full-length Human Leptin i.e., includes 21-residue N-terminal signal sequence
  • Unprocessed Full-length Platypus leptin i.e., includes 21-residue N-terminal signal sequence
  • a full length sequence of platypus leptin, including a 21-residue N-terminal signal sequence follows:
  • Leptin A200 is an Fc antibody fragment condensation product with leptin, as known in the art. See e.g., Lo et al., 2005 , Protein Eng. Design & Selection, 18:1-10.
  • the amino acid sequence of A200 is as follows:
  • Leptin A300 is metreleptin with substitutions W101Q and W139Q (N-terminal 1 Met counted as residue 1):
  • Leptin A400 is metreleptin with the serine residue at position 78 replaced with a cysteine residue, as set forth following:
  • Leptin A500 Research by a number of investigators including the inventors has focused on the effects on aggregation of residue substitution in leptin. See e.g., Ricci et al., 2006. “Mutational approach to improve physical stability of protein therapeutics susceptible to aggregation: Role of altered conformation in irreversible precipitation,” Book Chapter. In: M ISBEHAVING P ROTEINS : P ROTEIN (M IS )F OLDING , A GGREGATION, AND S TABILITY , Murphy R M, Tsai A M, Eds., New York. Springer. pp. 331-350, which is incorporated herein by reference and for all purposes. Accordingly, leptin A500 with sequence following has been used in certain compounds and methods described herein:
  • Leptin A100 Variants of Leptin A100 with the following amino acid substitutions follow:
  • H98S, W101Q, G113E, M137I, W139Q, and G146E (SEQ ID NO: 40) MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCSLPQASGLETLDSLGEVLEASGYST EVVALSRLQGSLQDILQQLDLSPEC.
  • W101Q, G113E, M137I, W139Q, and G146E (SEQ ID NO: 41) MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPQASGLETLDSLGEVLEASGYST EVVALSRLQGSLQDILQQLDLSPEC.
  • H98S, W101Q, M137I, W139Q, and G146E (SEQ ID NO: 42) MVPIQKVQDDTKTLIKTIVTRNDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCSLPQASGLETLDSLGGVLEASGYST EVVALSRLQGSLQDILQQLDLSPEC.
  • W101Q, G113E, M137I, W139Q, L143V, and G146E (SEQ ID NO: 43) MVPIQKVQDDTKTLIKTIVTRNDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPQASGLETLDSLGEVLEASGYST EVVALSRLQGSLQDILQQLDVSPEC.
  • H98S, W101Q, A102T, M137I, W139Q, and G146E (SEQ ID NO: 44) MVPIQKVQDDTKTLIKTIVTRNDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCSLPQTSGLETLDSLGGVLEASGYST EVVALSRLQGSLQDILQQLDLSPEC.
  • H98S, W101Q, D109E, G113E, and G146E (SEQ ID NO: 45) MVPIQKVQDDTKTLIKTIVTRNDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSC SLPQASGLETLESLGEVLEASGYST EVVALSRLQGSLQDMLWQLDLSPEC.
  • W101Q, M137I, W139Q, and G146E (SEQ ID NO: 46) MVPIQKVQDDTKTLIKTIVTRNDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPQASGLETLDSLGGVLEASGYS TEVVALSRLQGSLQDILQQLDLSPEC.
  • W101Q, M137I, W139Q, L143V, and G146E (SEQ ID NO: 47) MVPIQKVQDDTKTLIKTIVTRNDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPQASGLETLDSLGGVLEASGYS TEVVALSRLQGSLQDILQQLDVSPEC.
  • H98S, W101Q, A102T, G113E, and G146E (SEQ ID NO: 49) MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCSLPQTSGLETLDSLGEVLEASGYST EVVALSRLQGSLQDMLWQLDLSPEC.
  • W101Q, G113E, and W139Q (SEQ ID NO: 50) MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPQASGLETLDSLGEVLEASGYST EVVALSRLQGSLQDMLQQLDLSPGC.
  • W101Q, G113E, W139Q, and G146E (SEQ ID NO: 51) MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAV YQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPQASGLETLDSLGEVLEASGYST EVVALSRLQGSLQDMLQQLDLSPEC.
  • a series of chimeric polypeptides are described. These chimeric polypeptides are based on a wild type seal leptin polypeptide wherein at least one contiguous region of 1-30 amino acids of a wild type seal leptin sequence has been replaced with a contiguous region of 1-30 amino acids of a mature human leptin sequence.
  • a wild type seal leptin sequence includes the sequence of wild type seal leptin (SEQ ID NO:28) and the sequence of wild type seal leptin with an N-terminal methionine (SEQ ID NO:31).
  • a mature human leptin sequence useful for chimerizing wild type seal leptin as provided herein, includes the following sequences described above: mature human leptins (SEQ ID NO:12), mature human leptins with N-terminal methionine (SEQ ID NO:13), mature human leptin form 1 (SEQ ID NO:20), mature human leptin form 2 (SEQ ID NO:21), mature human leptin form 3 (SEQ ID NO:22), mature human leptin form 4 (SEQ ID NO:23), mature human leptin form 1 with N-terminal methionine (Metreleptin, or A100, SEQ ID NO:24), mature human leptin form 2 with N-terminal methionine (SEQ ID NO:25), mature human leptin form 3 with N-terminal methionine (SEQ ID NO:26), mature human leptin form 4 with N-terminal methionine (SEQ ID NO:27), A200 (SEQ ID NO
  • a series of chimeric polypeptides are described wherein at least one contiguous region of 1-30 amino acids of a wild type seal leptin sequence (SEQ ID NO. 28 or SEQ ID NO:31) has been replaced with a contiguous region of 1-30 amino acids of A100 (SEQ ID NO. 24).
  • a contiguous region of 1-30 amino acids can comprise any naturally or non-naturally occurring amino acid. Any combination of amino acids can be employed without restriction. That is, two or more amino acids in a contiguous region can be replaced with a naturally occurring amino acid, a non-naturally occurring amino acid, a conservative substitution, a non-conservative substitution or any combination thereof.
  • the chimeric polypeptides described herein have demonstrated biological activity, in addition to enhanced physical properties.
  • the seal-human chimeric polypeptides show leptin activity in vitro and in vivo.
  • the chimeric polypeptides also show enhanced stability and solubility compared to the mature human leptin polypeptides which are used to derive the sequences, as shown by the Examples.
  • Leptin activity includes leptin binding activity and leptin functional activity.
  • leptin analog compounds can have an IC 50 of about 200 nM or less, about 100 nM or less, or about 50 nM or less, or about 5 nM or less, or about 1 nM or less, in a leptin binding assay, such as that described herein.
  • IC 50 refers in the customary sense to the half maximal inhibitory concentration of a compound inhibiting a biological or biochemical function.
  • IC 50 refers to the concentration of a test compound which competes half of a known ligand from a specified receptor.
  • Leptin analog compounds can have an EC 50 of about 20 nM or less, about 10 nM or less, about 5 nM or less, about 1 nM or less, or about 0.1 nM or less, in a leptin functional assay, such as that described herein.
  • the term “EC 50 ” refers in the customary sense to the effective concentration of a compound which induces a response halfway between a baseline response and maximum response, as known in the art.
  • Helix 1 region of a mature human leptin polypeptide spans a contiguous region of 20 amino acids.
  • Helix 1 and Helix 3 are antiparallel helices that form part of Binding Site II of leptin to its receptor. This site interacts with the cytokine receptor homology domain (CRH) of the leptin receptor and is thought to be a major receptor binding site, but not involved in receptor activation.
  • CSH cytokine receptor homology domain
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 3-22 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 5-24 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:52:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 3-22 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 5-24 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:53:
  • the Helix 2 region of a mature human leptin polypeptide spans a region of 16 contiguous amino acids. This helix is buried in the 4-helix bundle as described in the original crystal structure paper by Zhang et al. (Nature 1997 387:206).
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 50-65 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 52-67 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:54:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 50-65 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 52-67 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:55:
  • Helix 3 region of a mature human leptin polypeptide spans a contiguous region of 22 amino acids.
  • Helix 3 and Helix 1 are antiparallel helices that form part of Binding Site II of leptin to its receptor. This site interacts with the cytokine receptor homology domain (CRH) of the leptin receptor and is thought to be a major receptor binding site, but not involved in receptor activation.
  • CSH cytokine receptor homology domain
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:29:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:32:
  • Helix 4 region of a mature human leptin polypeptide spans a contiguous region of 22 amino acids. Helix 4 is thought to form parts of Binding Site I and Binding Site III of leptin, both of which are important for receptor activation. See, for example, Peelman et al., 2004, J. Biol. Chem. 279: 41038.
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 120-141 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 122-143 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:56:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 120-141 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 122-143 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:57:
  • the AB Loop region of a mature human leptin polypeptide spans a contiguous region of 27 amino acids.
  • the AB Loop is thought to form part of Binding Site III as well as a small portion of Binding Site I of leptin. See, for example, Peelman et al., 2004, J. Biol. Chem. 279: 41038.
  • This region also contains the absolutely conserved motif GLDFIP (SEQ ID NO: 164).
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:58:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:59:
  • Loop 3-4 region of a mature human leptin polypeptide spans a contiguous region of 27 amino acids. Loop 3-4 is thought to contain a part of Binding Site III of leptin to its receptor. See, for example, Peelman et al., 2004, J. Biol. Chem. 279: 41038.
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 93-119 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 95-121 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:60:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 93-119 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 95-121 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:61:
  • a series of chimeric combination polypeptides are described. These chimeric combination polypeptides are based on a wild type seal leptin polypeptide wherein two or more contiguous regions of 1-30 amino acids of a wild type seal leptin sequence (for example, SEQ ID NO:28 or SEQ ID NO:31) have been replaced at each region with a contiguous region of 1-30 amino acids of a mature human leptin sequence.
  • Chimeric combination polypeptides can be engineered to demonstrate enhanced physical properties compared to the mature human leptin polypeptides which are used to derive the sequences, while retaining the biological activity of human leptin.
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 3-22 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 5-24 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:62:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 3-22 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 5-24 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:63:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:64:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:65:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 93-119 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 95-121 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:66:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 93-119 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 95-121 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:67:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 120-141 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 122-143 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:68:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 120-141 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 122-143 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:69:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 93-119 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 95-121 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:70:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 93-119 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 95-121 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:71:
  • the present disclosure relates to chimeric polypeptides that are based on wild type seal leptin with an incorporated AB Loop sequence, an incorporated Loop 3-4 sequence, and an incorporated helix 3 sequence from mature human leptin.
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide (SEQ ID NO:28), wherein the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24), the contiguous region spanning the amino acids at positions 93-119 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 95-121 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:72:
  • a chimeric polypeptide comprises the amino acid sequence of a wild type seal leptin polypeptide with an N-terminal methionine (SEQ ID NO:31), wherein the contiguous region spanning the amino acids at positions 23-49 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 25-51 of A100 (SEQ ID NO:24), the contiguous region spanning the amino acids at positions 93-119 of SEQ ID NO:31 has been replaced with a contiguous region spanning the amino acids at positions 95-121 of A100 (SEQ ID NO:24), and the contiguous region spanning the amino acids at positions 71-92 of SEQ ID NO:28 has been replaced with a contiguous region spanning the amino acids at positions 73-94 of A100 (SEQ ID NO:24).
  • a chimeric polypeptide comprises the sequence described in SEQ ID NO:73:
  • the chimeric polypeptides provided by the invention contain a Cys to Ser amino acid substitution at position 30 of the wild type seal polypeptide sequence.
  • chimeric polypeptides are provided:
  • each of the polypeptides disclosed herein are also contemplated to include (optionally) a methionine at the N-terminus in frame with the naturally-occurring first amino acid thereof.
  • a methionine at the N-terminus in frame with the naturally-occurring first amino acid thereof.
  • metreleptin consists of mature human leptin to which has been added an N-terminal methionine, as disclosed in SEQ ID NO:24.
  • a methionine residue may be included at the N-terminus of any of the amino acid sequences and Formulae disclosed herein throughout.
  • chimeric polypeptide analogs are provided.
  • a chimeric polypeptide analog can have at least 80%, for example 80%, 85%, 90%, 95%, 98% or even higher, sequence identity relative to a parent chimeric polypeptide.
  • the parent chimeric polypeptide is a polypeptide set out in SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79, SEQ ID NO:80, ID NO:29, S
  • a chimeric polypeptide analog may have at least 80%, for example 80%, 85%, 90%, 95%, 98% or even higher, sequence identity relative to any chimeric polypeptide selected from the group consisting of SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, and SEQ ID NO:33.
  • a chimeric polypeptide analog may have at least 80%, for example 80%, 85%, 90%, 95%, 98% or even higher, sequence identity relative to the chimeric polypeptide set forth in SEQ ID NO:33.
  • a chimeric polypeptide analog may have at least 90% sequence identity relative to the a chimeric polypeptide set forth in SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, or SEQ ID NO:33. In some embodiments, a chimeric polypeptide analog may have at least 90% sequence identity relative to the chimeric polypeptide set forth in SEQ ID NO:33.
  • chimeric polypeptide analogs may be designed, prepared, and used in accordance with the invention in which 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or even 21 amino acids of a chimeric polypeptide selected from the group consisting of: SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:
  • the term “conservative” in the context of amino acid substitutions refers to substitution which maintains properties of charge type (e.g., anionic, cationic, neutral, polar and the like), hydrophobicity or hydrophilicity, bulk (e.g., van der Waals contacts and the like), and/or functionality (e.g., hydroxy, amine, sulhydryl and the like).
  • charge type e.g., anionic, cationic, neutral, polar and the like
  • hydrophobicity or hydrophilicity e.g., hydrophobicity or hydrophilicity
  • bulk e.g., van der Waals contacts and the like
  • functionality e.g., hydroxy, amine, sulhydryl and the like.
  • non-conservative refers to an amino acid substitution which is not conservative.
  • the invention provides chimeric polypeptide analogs comprising at least one contiguous region of 1-30 amino acids from a mature human leptin analog sequence that contains at least one amino acid substitution at a position where divergence is observed in a corresponding position in a leptin from another species.
  • murine leptins, rat leptins, bovine leptins, porcine leptins, and rhesus monkey leptins are each substantially homologous to human leptins; in particular, the mature forms of these leptins are substantially homologous to mature leptins, and further, particularly near the N-terminal portion of the protein.
  • mature human leptins e.g., SEQ ID NO:20
  • leptin analogs may be designed and prepared in which one or more amino acids at positions which are divergent at the corresponding position(s) in a leptin from one or more of such species are substituted with the amino acid(s) at such corresponding divergent positions.
  • a human mature leptin protein according to SEQ ID NO:20 wherein the first amino acid is valine and the amino acid at position 146 is cysteine
  • another amino acid such as a conservative amino acid or a non-conservative amino acid
  • rat leptin differs from mature human leptin form 1 (SEQ ID NO:20) at the following positions: 4, 32, 33, 35, 50, 68, 71, 74, 77, 78, 89, 97, 100, 101, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138 and 145.
  • another amino acid such as a conservative amino acid or a non-conservative amino acid
  • the positions from both mature rat leptin (SEQ ID NO:16) and mature murine leptin form 1 (SEQ ID NO:2) which diverge from the mature human leptin form 1 (SEQ ID NO:20) are: 4, 32, 33, 35, 50, 64, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145.
  • another amino acid such as a conservative amino acid or a non-conservative amino acid
  • amino acids found in rhesus monkey mature leptin (SEQ ID NO:14) which diverge from mature human leptin form 1 (SEQ ID NO:20) are (with amino acid residues noted in parentheses in one letter amino acid abbreviation): 8 (S), 35 (R), 48(V), 53(Q), 60(I), 66(I), 67(N), 68((L), 89(L), 100(L), 108(E), 112 (D), and 118 (L).
  • a leptin such as mature human leptin form 1 (SEQ ID NO:20) having one or more of the rhesus monkey divergent amino acids replaced with another amino acid, such as the amino acids in parentheses, may be employed in designing and preparing leptin analogs comprised by the chimeric polypeptides in accordance with the invention.
  • certain rhesus divergent amino acids are also those found in, for example, the above mature murine leptin form 1 (positions 35, 68, 89, 100 and 112).
  • leptin analogs in which one or more amino acids at positions 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, and 145 of, e.g., mature human leptin form 1 (SEQ ID NO:20) are replaced by the corresponding amino acid(s) at such position(s) in murine or rhesus monkey leptins (e.g., SEQ ID NO:2 and/or SEQ ID NO:14).
  • SEQ ID NO:20 mature human leptin form 1
  • chimeric polypeptide analogs may be designed and prepared to comprise contiguous regions of amino acids from human leptin analogs.
  • the invention provides chimeric polypeptide analogs based on a wild type seal leptin polypeptide wherein at least one contiguous region of 1-30 amino acids of a wild type seal leptin sequence has been replaced with a contiguous region of 1-30 amino acids of a mature human leptin analog sequence, and wherein the mature human leptin analog sequence contains at least one amino acid substitution at a position where divergence is observed in a corresponding position in a leptin from another species.
  • Chimeric polypeptide analogs comprising two or more contiguous regions of 1-30 amino acids of a mature human leptin analog sequence are also provided.
  • Chimeric polypeptides to which a chemical moiety is attached are polypeptide derivatives. Derivatization of chimeric polypeptides by attachment of one or more chemical moieties has been found to provide some advantage under certain circumstances, such as increasing the stability and circulation time of the therapeutic protein and decreasing immunogenicity and propensity for, for example, generation of neutralizing antibodies and/or incidence of injection site reactions. See, e.g., WO 98/28427, US2007/0020284, U.S. Pat. No. 4,179,337, Davis et al., issued Dec. 18, 1979. For a review, see Abuchowski et al., in E NZYMES AS D RUGS . (J. S. Holcerberg and J. Roberts, eds. pp. 367-383 (1981)); Francis et al., Id.
  • Polypeptide derivatives may constitute polypeptides to which a chemical modification has been made of one or more of its amino acid side groups, ⁇ -carbon atoms, terminal amino group, or terminal carboxylic acid group.
  • a chemical modification includes, but is not limited to, attaching one or more chemical moieties, creating new bonds, and removing one or more chemical moieties.
  • Modifications at amino acid side groups include, without limitation, alkylation, acylation, ester formation, amide formation, maleimide coupling, acylation of lysine ⁇ -amino groups, N-alkylation of arginine, histidine, or lysine, alkylation of glutamic or aspartic carboxylic acid groups, and deamidation of glutamine or asparagine.
  • Modifications of the terminal amino include, without limitation, the desamino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications. Modifications of the terminal amino include, without limitation, the desamino, N-lower alkyl, N-di-lower alkyl, and N-acyl modifications, such as alkylacyls, branched alkylacyls, alkylaryl-acyls. Modifications of the terminal carboxy group include, without limitation, the amide, lower alkyl amide, dialkyl amide, arylamide, alkylarylamide and lower alkyl ester modifications. Lower alkyl is C 1 -C 4 alkyl. Furthermore, one or more side groups, or terminal groups, may be protected by protective groups known to the ordinarily-skilled synthetic chemist.
  • the ⁇ -carbon of an amino acid may be mono- or dimethylated.
  • Such derivatives include polypeptides conjugated to one or more water soluble polymer molecules, such as polyethylene glycol (“PEG”) or fatty acid chains of various lengths (e.g., stearyl, palmitoyl, octanoyl), by the addition of polyamino acids, such as poly-his, poly-arg, poly-lys, and poly-ala, or by addition of small molecule substituents include short alkyls and constrained alkyls (e.g., branched, cyclic, fused, adamantyl), and aromatic groups.
  • the water soluble polymer molecules will have a molecular weight ranging from about 500 Daltons to about 60,000 Daltons.
  • Such polymer-conjugations may occur singularly at the N- or C-terminus or at the side chains of amino acid residues within the sequence of a chimeric polypeptide as disclosed herein.
  • Substitution of one or more amino acids with lysine, aspartic acid, glutamic acid, or cysteine may provide additional sites for derivatization. See, e.g., U.S. Pat. Nos. 5,824,784 and 5,824,778.
  • a chimeric polypeptide may be conjugated to one, two, or three polymer molecules.
  • the water soluble polymer molecules are linked to an amino, carboxyl, or thiol group, and may be linked by N or C termini, or at the side chains of lysine, aspartic acid, glutamic acid, or cysteine.
  • the water soluble polymer molecules may be linked with diamine and dicarboxylic groups.
  • a chimeric polypeptide is conjugated to one, two, or three PEG molecules through an epsilon amino group on a lysine amino acid.
  • Polypeptide derivatives also include polypeptides with chemical alterations to one or more amino acid residues.
  • chemical alterations include amidation, glycosylation, acylation, sulfation, phosphorylation, acetylation, and cyclization.
  • the chemical alterations may occur singularly at the N- or C-terminus or at the side chains of amino acid residues within the sequence of a leptin.
  • the C-terminus of these peptides may have a free —OH or —NH 2 group.
  • the N-terminal end may be capped with an isobutyloxycarbonyl group, an isopropyloxycarbonyl group, an n-butyloxycarbonyl group, an ethoxycarbonyl group, an isocaproyl group (“isocap”), an octanyl group, an octyl glycine group (denoted as “G(Oct)” or “octylGly”), an 8-aminooctanic acid group, a dansyl, and/or a Fmoc group.
  • cyclization can be through the formation of disulfide bridges. Alternatively, there may be multiple sites of chemical alteration along the polypeptide amino acid sequence.
  • chimeric polypeptides are chemically altered to include a Bolton-Hunter group.
  • Bolton-Hunter reagents are known in the art (“Radioimmunoassay and related methods,” A. E. Bolton and W. M. Hunter, Chapter 26 of H ANDBOOK OF E XPERIMENTAL I MMUNOLOGY , V OLUME I, I MMUNOCHEMISTRY , edited by D. M. Weir, Blackwell Scientific Publications, 1986), and may be used to introduce tyrosine-like moieties with a neutral linkage, through amino-terminal ⁇ -amino groups or ⁇ -amino groups of lysine.
  • the N-terminal end of a polypeptide is modified with a Bolton-Hunter group.
  • an internal lysine residue is modified with a Bolton-Hunter group.
  • Bolton-Hunter reagents used for polypeptide modification are commercially available, and may include, but are not limited to, water-soluble Bolton-Hunter reagent, Sulfosuccinimidyl-3-[4-hydrophenyl]propionate (Pierce Biotechnology, Inc., Rockford, Ill.) and Bolton-Hunter reagent-2, N-Succinimidyl 3-(4-hydroxy-3-iodophenyl) Priopionate (Wako Pure Chemical Industries, Ltd., Japan, catalog #199-09341).
  • An exemplary Bolton-Hunter group conjugated through an amide linkage to a polypeptide is illustrated below, wherein the dashed line passes through the amide bond:
  • Polypeptides may be iodinated (such as radiolabeled with 125 I) before or after Bolton-Hunter modification.
  • Polypeptide derivatives may include one or more modifications of a “non-essential” amino acid residue.
  • a “non-essential” amino acid residue is a residue that can be altered, e.g., derivatized, without abolishing or substantially reducing the activity (e.g., the agonist activity) of the chimeric polypeptide.
  • the chimeric polypeptides of the invention may include derivatizations of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residues; of these, one or more amino acid residues may be non-essential amino acid residues.
  • polypeptides of the invention may be derivatized such that they include additions of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids without abolishing or substantially reducing the activity of the polypeptide. Additionally, such non-essential amino acid residues may be substituted with an amino acid residue that is amenable to derivatization as described throughout.
  • amino acid As used throughout, “amino acid,” “amino acid residue” and the like refer to natural amino acids, unnatural amino acids, and modified amino acids. Unless stated to the contrary, any reference to an amino acid, generally or specifically by name, includes reference to both the D and the L stereoisomers if their structure allow such stereoisomeric forms.
  • Natural amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), Lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr) and valine (Val).
  • Unnatural amino acids include, but are not limited to homolysine, homoarginine, homoserine, azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2′-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methyl
  • Additional unnatural amino acids include modified amino acid residues which are chemically blocked, reversibly or irreversibly, or chemically modified on their N-terminal amino group or their side chain groups, as for example, N-methylated D and L amino acids or residues wherein the side chain functional groups are chemically modified to another functional group.
  • modified amino acids include methionine sulfoxide; methionine sulfone; aspartic acid-(beta-methyl ester), a modified amino acid of aspartic acid; N-ethylglycine, a modified amino acid of glycine; or alanine carboxamide, a modified amino acid of alanine. Additional residues that can be incorporated are described in Sandberg et al., J. Med. Chem. 41: 2481-91, 1998.
  • chemical moieties suitable for such derivatization of the chimeric polypeptides include, for example, various water soluble polymers.
  • the polymer will be pharmaceutically acceptable.
  • One skilled in the art will be able to select the desired polymer based on such considerations as whether the polymer/protein conjugate will be used therapeutically, and if so, the desired dosage, circulation time, resistance to proteolysis, and other considerations.
  • the effectiveness of the derivatization may be ascertained by administering the derivatized polypeptide, in the desired form (i.e., by osmotic pump, or, more preferably, by injection or infusion, or, further formulated for oral, pulmonary or nasal delivery, for example), and observing biological effects and biological responses as described herein.
  • Such a water soluble polymer may be selected from the group consisting of, for example, polyethylene glycol, copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols and polyvinyl alcohol.
  • Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. Also, succinate, styrene, and hydroxyethyl starch may also be used.
  • chimeric polypeptides in accordance with the invention may be prepared by attaching polyaminoacids or branch point amino acids.
  • the polyaminoacid may be an additional carrier protein, such as an Fc moiety, which can serve to also increase the circulation half life of the chimeric polypeptide.
  • additional carrier protein such as an Fc moiety
  • such polyaminoacids may be selected from the group consisting of serum albumin (such as human serum albumin), an additional antibody or portion thereof (e.g. the Fc region), or other polyaminoacids, e.g. polylysines.
  • the location of attachment of the polyaminoacid may be at the N-terminus of polypeptide, or C-terminus, or other places in between, and also may be connected by a chemical “linker” moiety to the polypeptide, such as a peptidic linker or a non-peptidic linker.
  • the polymer may be of any molecular weight, and may be branched or unbranched.
  • the preferred molecular weight is between about 2 kilodaltons (kDa) and about 100 kDa (the term “about” indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing.
  • the polyethylene glycol is between about 2 kDa and about 60 kDa.
  • the polyethylene glycol is between about 2 kDa and about 40 kDa.
  • the polyethylene glycol is between about 5 kDa and about 40 kDa.
  • the polyethylene glycol is between about 10 kDa and about 40 kDa. In certain embodiments, the polyethylene glycol is between about 5 kDa and about 30 kDa. In certain embodiments, the polyethylene glycol is between about 5 kDa and about 20 kDa. In certain embodiments, the polyethylene glycol is between about 10 kDa and about 20 kDa. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, solubility characteristics, the effects, if any, on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol attached to a leptin and/or to a chimeric polypeptide of the invention).
  • the desired therapeutic profile e.g., the duration of sustained release desired, solubility characteristics, the effects, if any, on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol attached to a leptin and
  • Additional considerations that may influence the selection of a PEG of a particular molecular weight which may be attached to a chimeric polypeptide to generate a chimeric derivative in accordance with the invention include the extent to which such a molecular weight PEG may: mitigate aggregation and/or increase the solubility of the chimeric polypeptide, when present in a pharmaceutically acceptable composition or formulation, or when exposed to physiological fluids or tissues upon administration to a subject (such as by injection); mitigate the incidence of injection site reactions caused by administration of the chimeric polypeptide upon administration to a subject by injection; mitigate the generation of neutralizing antibodies that may be raised against the chimeric polypeptide as a result of administration of such a chimeric polypeptide to a subject; and the like.
  • the number of polymer molecules so attached may vary, and one skilled in the art will be able to ascertain the resultant effect on function.
  • One may mono-derivatize, or may provide for a di-, tri-, tetra- or some combination of derivatization, with the same or different chemical moieties (e.g., polymers, such as different weights of polyethylene glycols).
  • the proportion of polymer molecules to chimeric polypeptide molecules to be derivatized will vary, as will their concentrations in the reaction mixture.
  • the optimum ratio in terms of efficiency of reaction in that there is no excess unreacted chimeric polypeptide or polymer, will be determined by factors such as the desired degree of derivatization (e.g., mono, di-, tri-, etc.), the molecular weight of the polymer selected, whether the polymer is branched or unbranched, and the reaction conditions.
  • the chemical moieties should be attached to the chimeric polypeptide with consideration of the effects on functional or antigenic domains of the chimeric polypeptide.
  • attachment methods available to those skilled in the art.
  • EP 0 401 384 herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., 1992 , Exp. Hematol. 20:1028-1035 (reporting pegylation of GM-CSF using tresyl chloride).
  • polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group.
  • Reactive groups are those to which an activated polyethylene glycol molecule may be bound.
  • the amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residue.
  • Those having a free carboxyl group may include aspartic acid residues, glutamic acid residues, and the C-terminal amino acid residue.
  • Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecule(s).
  • Preferred for therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group. Attachment at residues important for receptor binding should be avoided if receptor binding is desired.
  • polyethylene glycol as an illustration of the present compositions, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to chimeric polypeptide molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein.
  • the method of obtaining the N-terminally pegylated preparation i.e., separating this moiety from other monopegylated moieties if necessary
  • Selective N-terminal chemical modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein.
  • substantially selective derivatization of the protein at the N-terminus with a carbonyl group containing polymer is achieved.
  • one may selectively N-terminally pegylate the protein by performing the reaction at a pH which allows one to take advantage of the pK a differences between the ⁇ -amino group of the lysine residues and that of the ⁇ -amino group of the N-terminal residue of the protein.
  • the water soluble polymer may be of the type described above, and should have a single reactive aldehyde for coupling to the protein.
  • Polyethylene glycol propionaldehyde, containing a single reactive aldehyde, may be used.
  • the chimeric polypeptides described herein can be designed at the amino acid level. These sequences can then be back translated using a variety of software products known in the art such that the nucleotide sequence is optimized for the desired expression host, e.g. based protein expression, codon optimization, restriction site content. For example, the nucleotide sequence can be optimized for E. coli based protein expression and for restriction site content. Based on the nucleotide sequence of interest, overlapping oligonucleotides can be provided for multistep PCR, as known in the art. These oligonucleotides can be used in multiple PCR reactions under conditions well known in the art to build the cDNA encoding the protein of interest.
  • For one example is 1X Amplitaq Buffer, 1.3 mM MgCl 2 , 200 uM dNTPs, 4 U Amplitaq Gold, 0.2 uM of each primer (AmpliTaq Gold, ABI), with cycling parameters: (94 C:30 s, 58 C:1 min, 72 C: 1 min), 35 cycles.
  • Restriction sites can be added to the ends of the PCR products for use in vector ligation as known in the art.
  • Specific sites can include Nde1 and Xho1, such that the cDNA can then be in the proper reading frame in a pET45b expression vector (Novagen). By using these sites, any N-terminal His Tags that are in this vector can be removed as the translation start site would then be downstream of the tag.
  • verification can be conduct by sequencing using e.g., T7 promoter primer, T7 terminator primer and standard ABI BigDye Term v3.1 protocols as known in the art.
  • Sequence information can be obtained from e.g., an ABI 3730 DNA Analyzer and can be analyzed using Vector NTI v.10 software (Invitrogen). Expression constructs can be designed in a modular manner such that linker sequences can be easily cut out and changed, as known in the art.
  • Protease recognition sites known in the art or described herein, can be incorporated into constructs useful for the design, construction, manipulation and production of recombinant chimeric polypeptides described herein.
  • chimeric polypeptides described herein may be prepared using biological, chemical, and/or recombinant DNA techniques that are known in the art. Exemplary methods are described herein and in U.S. Pat. No. 6,872,700; WO 2007/139941; WO 2007/140284; WO 2008/082274; WO 2009/011544; and US Publication No. 2007/0238669, the disclosures of which are incorporated herein by reference in their entireties and for all purposes. Other methods for preparing the compounds are set forth herein.
  • the chimeric polypeptides described herein may be prepared using standard solid-phase peptide synthesis techniques, such as an automated or semiautomated peptide synthesizer.
  • the chimeric polypeptides may be produced by non-biological peptide synthesis using amino acids and/or amino acid derivatives having reactive side-chains protected, the non-biological peptide synthesis comprising step-wise coupling of the amino acids and/or the amino acid derivatives to form a polypeptide according to the first aspect having reactive side-chains protected, removing the protecting groups from the reactive side-chains of the polypeptide, and folding of the polypeptide in aqueous solution.
  • normal amino acids e.g.
  • glycine, alanine, phenylalanine, isoleucine, leucine and valine) and pre-protected amino acid derivatives are used to sequentially build a polypeptide sequence, in solution or on a solid support in an organic solvent.
  • the protecting groups are removed and the polypeptide is allowed to fold in an aqueous solution.
  • an alpha-N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at RT in an inert solvent (e.g., dimethylformamide, N-methylpyrrolidinone, methylene chloride, and the like) in the presence of coupling agents (e.g., dicyclohexylcarbodiimide, 1-hydroxybenzo-triazole, and the like) in the presence of a base (e.g., diisopropylethylamine, and the like).
  • an inert solvent e.g., dimethylformamide, N-methylpyrrolidinone, methylene chloride, and the like
  • coupling agents e.g., dicyclohexylcarbodiimide, 1-hydroxybenzo-triazole, and the like
  • a base e.g., diisopropylethylamine, and the like
  • the alpha-N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent (e.g., trifluoroacetic acid, piperidine, and the like) and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain.
  • a reagent e.g., trifluoroacetic acid, piperidine, and the like
  • Suitable N-protecting groups are well known in the art, such as t-butyloxycarbonyl (tBoc) fluorenylmethoxycarbonyl (Fmoc), and the like.
  • tBoc t-butyloxycarbonyl
  • Fmoc fluorenylmethoxycarbonyl
  • the solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, Calif.).
  • Solid phase peptide synthesis can be used for the chimeric polypeptides, since in general solid phase synthesis is a straightforward approach with excellent scalability to commercial scale.
  • Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, Calif.) using the NMP/HOBt (Option 1) system and tBoc or Fmoc chemistry (See Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, Version 1.3B Jul. 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, Calif.) with capping.
  • an automatic peptide synthesizer Model 430A, Applied Biosystems Inc., Foster City, Calif.
  • NMP/HOBt Option 1
  • tBoc or Fmoc chemistry See Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer,
  • Boc-peptide-resins may be cleaved with HF ( ⁇ 5° C. to 0° C., 1 hour).
  • the peptide may be extracted from the resin with alternating water and acetic acid, and the filtrates lyophilized.
  • the Fmoc-peptide resins may be cleaved according to standard methods (e.g., Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12).
  • Peptides may also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville, Ky.).
  • Non-peptide compounds may be prepared by art-known methods.
  • phosphate-containing amino acids and peptides containing such amino acids may be prepared using methods known in the art, such as described in Bartlett et al, 1986 , Biorg. Chem. 14:356-377.
  • the chimeric polypeptides may alternatively be produced by recombinant techniques well known in the art. See, e.g., Sambrook et al., 1989 (Id.). These chimeric polypeptides produced by recombinant technologies may be expressed from a polynucleotide.
  • polynucleotides including DNA and RNA, that encode such chimeric polypeptides may be obtained from the wild-type cDNA, e.g. human leptin, taking into consideration the degeneracy of codon usage, and may further be engineered as desired to incorporate the indicated substitutions.
  • These polynucleotide sequences may incorporate codons facilitating transcription and translation of mRNA in microbial hosts.
  • Non-peptide compounds useful in the present invention may be prepared by art-known methods. For example, phosphate-containing amino acids and peptides containing such amino acids may be prepared using methods known in the art. See, e.g., Bartlett and Landen, 1986 , Bioorg. Chem. 14: 356-77.
  • a variety of expression vector/host systems may be utilized to contain and express a chimeric polypeptide coding sequence. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transfected with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (e.g., Ti or pBR322 plasmid); or animal cell systems.
  • microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transfected with virus expression vectors (e.g., cauliflower mosaic virus, CaMV;
  • Mammalian cells that are useful in recombinant protein productions include, but are not limited to, VERO cells, HeLa cells, Chinese hamster ovary (CHO) cell lines, COS cells (such as COS-7), WI 38, BHK, HepG2, 3T3, RIN, MDCK, A549, PC12, K562 and 293 cells. Exemplary protocols for the recombinant expression of the protein are described herein and/or are known in the art.
  • polynucleotide sequences are useful in generating new and useful viral and plasmid DNA vectors, new and useful transformed and transfected prokaryotic and eukaryotic host cells (including bacterial, yeast, and mammalian cells grown in culture), and new and useful methods for cultured growth of such host cells capable of expression of the present chimeric polypeptides.
  • the polynucleotide sequences encoding chimeric polypeptides herein may be useful for gene therapy in instances where underproduction of chimeric polypeptides would be alleviated, or the need for increased levels of such would be met.
  • the present invention also provides for processes for recombinant DNA production of the present chimeric polypeptides.
  • a process for producing the chimeric polypeptides from a host cell containing nucleic acids encoding the chimeric polypeptide comprising: (a) culturing the host cell containing polynucleotides encoding the chimeric polypeptide under conditions facilitating the expression of the DNA molecule; and (b) obtaining the chimeric polypeptide.
  • Host cells may be prokaryotic or eukaryotic and include bacteria, mammalian cells (such as Chinese Hamster Ovary (CHO) cells, monkey cells, baby hamster kidney cells, cancer cells or other cells), yeast cells, and insect cells.
  • mammalian cells such as Chinese Hamster Ovary (CHO) cells, monkey cells, baby hamster kidney cells, cancer cells or other cells
  • yeast cells such as yeast cells, and insect cells.
  • Mammalian host systems for the expression of the recombinant protein also are well known to those of skill in the art. Host cell strains may be chosen for a particular ability to process the expressed protein or produce certain post-translation modifications that will be useful in providing protein activity. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and acylation. Post-translational processing, which cleaves a “prepro” form of the protein, may also be important for correct insertion, folding and/or function. Different host cells, such as CHO, HeLa, MDCK, 293, W138, and the like, have specific cellular machinery and characteristic mechanisms for such post-translational activities, and may be chosen to ensure the correct modification and processing of the introduced foreign protein.
  • a yeast system may be employed to generate the chimeric polypeptides of the present invention.
  • the coding region of the chimeric polypeptides DNA is amplified by PCR.
  • a DNA encoding the yeast pre-pro-alpha leader sequence is amplified from yeast genomic DNA in a PCR reaction using one primer containing nucleotides 1-20 of the alpha mating factor gene and another primer complementary to nucleotides 255-235 of this gene (Kurjan and Herskowitz, 1982 , Cell, 30:933-43).
  • the pre-pro-alpha leader coding sequence and chimeric polypeptide coding sequence fragments are ligated into a plasmid containing the yeast alcohol dehydrogenase (ADH2) promoter, such that the promoter directs expression of a fusion protein consisting of the pre-pro-alpha factor fused to the mature chimeric polypeptide.
  • ADH2 yeast alcohol dehydrogenase
  • the vector further includes an ADH2 transcription terminator downstream of the cloning site, the yeast “2-micron” replication origin, the yeast leu-2d gene, the yeast REP1 and REP2 genes, the E.
  • the coli beta-lactamase gene and an E. coli origin of replication.
  • the beta-lactamase and leu-2d genes provide for selection in bacteria and yeast, respectively.
  • the leu-2d gene also facilitates increased copy number of the plasmid in yeast to induce higher levels of expression.
  • the REP1 and REP2 genes encode proteins involved in regulation of the plasmid copy number.
  • the DNA construct described in the preceding paragraph is transformed into yeast cells using a known method, e.g., lithium acetate treatment (Steams et al., 1990 ,. Meth. Enz. 185: 280-297).
  • the ADH2 promoter is induced upon exhaustion of glucose in the growth media (Price et al., 1987 , Gene 55:287).
  • the pre-pro-alpha sequence effects secretion of the fusion protein from the cells.
  • the yeast KEX2 protein cleaves the pre-pro sequence from the mature chimeric polypeptides (Bitter et al., 1984 , Proc. Natl. Acad. Sci. USA 81:5330-5334).
  • Chimeric polypeptides of the invention may also be recombinantly expressed in yeast, e.g., Pichia, using a commercially available expression system, e.g., the Pichia Expression System (Invitrogen, San Diego, Calif.), following the manufacturer's instructions. This system also relies on the pre-pro-alpha sequence to direct secretion, but transcription of the insert is driven by the alcohol oxidase (AOX1) promoter upon induction by methanol.
  • AOX1 alcohol oxidase
  • the secreted chimeric polypeptide is purified from the yeast growth medium by, e.g., the methods used to purify said chimeric polypeptide from bacterial and mammalian cell supernatants.
  • the DNA encoding a chimeric polypeptide may be cloned into a baculovirus expression vector, e.g. pVL1393 (PharMingen, San Diego, Calif.).
  • This chimeric-polypeptide-encoding vector is then used according to the manufacturer's directions (PharMingen) or known techniques to infect Spodoptera frugiperda cells, grown for example in sF9 protein-free media, and to produce recombinant protein.
  • the protein is purified and concentrated from the media using methods known in the art, e.g.
  • heparin-Sepharose column Pharmacia, Piscataway, N.J.
  • sequential molecular sizing columns Amicon, Beverly, Mass.
  • resuspended in appropriate solution e.g. PBS.
  • SDS-PAGE analysis can be used to characterize the protein, for example by showing a single band that confirms the size of the desired chimeric polypeptide, as can full amino acid amino acid sequence analysis, e.g. Edman sequencing on a Proton 2090 Peptide Sequencer, or confirmation of its N-terminal sequence.
  • the DNA sequence encoding the predicted mature chimeric polypeptide may be cloned into a plasmid containing a desired promoter and, optionally, a leader sequence (see, e.g., Better et al., 1988 , Science 240:1041-1043). The sequence of this construct may be confirmed by automated sequencing.
  • the plasmid is then transformed into E. coli , strain MC1061, using standard procedures employing CaCl2 incubation and heat shock treatment of the bacteria (Sambrook et al., Id.). The transformed bacteria are grown in LB medium supplemented with carbenicillin, and production of the expressed protein is induced by growth in a suitable medium. If present, the leader sequence will affect secretion of the mature chimeric polypeptide and be cleaved during secretion. The secreted recombinant chimeric polypeptide is purified from the bacterial culture media by the method described herein.
  • the chimeric polypeptides may be expressed in an insect system.
  • Insect systems for protein expression are well known to those of skill in the art.
  • Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.
  • the chimeric polypeptide coding sequence is cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter.
  • Successful insertion of a chimeric polypeptide will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat.
  • the recombinant viruses are then used to infect S.
  • frugiperda cells or Trichoplusia larvae in which a chimeric polypeptide of the present invention is expressed (Smith et al., 1983 , J. Virol. 46:584; Engelhard et al., 1994 , Proc. Natl. Acad. Sci. USA 91:3224-3227).
  • the DNA sequence encoding the chimeric polypeptides may be amplified by PCR and cloned into an appropriate vector, for example, pGEX-3X (Pharmacia, Piscataway, N.J.).
  • the pGEX vector is designed to produce a fusion protein comprising glutathione-S-transferase (GST), encoded by the vector, and a protein encoded by a DNA fragment inserted into the vector's cloning site.
  • the primers for the PCR may be generated to include, for example, an appropriate cleavage site.
  • the recombinant fusion protein may then be cleaved from the GST portion of the fusion protein.
  • the pGEX-3 ⁇ /chimeric polypeptide construct is transformed into E. coli XL-1 Blue cells (Stratagene, La Jolla, Calif.), and individual transformants are isolated and grown at 37° C. in LB medium (supplemented with carbenicillin) to an optical density at wavelength 600 nm of 0.4, followed by further incubation for 4 hours in the presence of 0.5 mM Isopropyl beta-D-thiogalactopyranoside (Sigma Chemical Co., St. Louis, Mo.). Plasmid DNA from individual transformants is purified and partially sequenced using an automated sequencer to confirm the presence of the desired chimeric polypeptide-encoding gene insert in the proper orientation.
  • the fusion protein when expected to be produced as an insoluble inclusion body in the bacteria, may be purified as described above or as follows. Cells are harvested by centrifugation; washed in 0.15 M NaCl, 10 mM Tris, pH 8, 1 mM EDTA; and treated with 0.1 mg/mL lysozyme (Sigma Chemical Co.) for 15 min. at RT. The lysate is cleared by sonication, and cell debris is pelleted by centrifugation for 10 min. at 12,000 ⁇ g. The fusion protein-containing pellet is resuspended in 50 mM Tris, pH 8, and 10 mM EDTA, layered over 50% glycerol, and centrifuged for 30 min. at 6000 ⁇ g.
  • the pellet is resuspended in standard phosphate buffered saline solution (PBS) free of Mg++ and Ca++.
  • PBS phosphate buffered saline solution
  • the fusion protein is further purified by fractionating the resuspended pellet in a denaturing SDS polyacrylamide gel (Sambrook et al., supra). The gel is soaked in 0.4 M KCl to visualize the protein, which is excised and electroeluted in gel-running buffer lacking SDS. If the GST/chimeric polypeptide fusion protein is produced in bacteria as a soluble protein, it may be purified using the GST Purification Module (Pharmacia Biotech).
  • the fusion protein may be subjected to digestion to cleave the GST from the mature chimeric polypeptide.
  • the digestion reaction (20-40 ⁇ g fusion protein, 20-30 units human thrombin (4000 U/mg (Sigma) in 0.5 mL PBS) is incubated 16-48 hrs. at RT and loaded on a denaturing SDS-PAGE gel to fractionate the reaction products. The gel is soaked in 0.4 M KCl to visualize the protein bands.
  • the identity of the protein band corresponding to the expected molecular weight of the chimeric polypeptide may be confirmed by partial amino acid sequence analysis using an automated sequencer (Applied Biosystems Model 473A, Foster City, Calif.).
  • 293 cells may be co-transfected with plasmids containing the chimeric polypeptides cDNA in the pCMV vector (5′ CMV promoter, 3′ HGH poly A sequence) and pSV2neo (containing the neo resistance gene) by the calcium phosphate method.
  • the vectors should be linearized with ScaI prior to transfection.
  • an alternative construct using a similar pCMV vector with the neo gene incorporated can be used.
  • Stable cell lines are selected from single cell clones by limiting dilution in growth media containing 0.5 mg/mL G418 (neomycin-like antibiotic) for 10-14 days. Cell lines are screened for chimeric polypeptides expression by ELISA or Western blot, and high-expressing cell lines are expanded for large scale growth.
  • G418 neomycin-like antibiotic
  • the transformed cells are used for long-term, high-yield protein production and as such stable expression is desirable.
  • the cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media.
  • the selectable marker is designed to confer resistance to selection, and its presence allows growth and recovery of cells that successfully express the introduced sequences. Resistant clumps of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell.
  • selection systems may be used to recover the cells that have been transformed for recombinant protein production.
  • selection systems include, but are not limited to, HSV thymidine kinase, hypoxanthine-guanine phosphoribosyltransferase and adenine phosphoribosyltransferase genes, in tk-, hgprt- or aprt-cells, respectively.
  • anti-metabolite resistance can be used as the basis of selection for dhfr, that confers resistance to methotrexate; gpt, that confers resistance to mycophenolic acid; neo, that confers resistance to the aminoglycoside, G418; also, that confers resistance to chlorsulfuron; and hygro, that confers resistance to hygromycin.
  • Additional selectable genes that may be useful include trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine.
  • Markers that give a visual indication for identification of transformants include anthocyanins, beta-glucuronidase and its substrate, GUS, and luciferase and its substrate, luciferin.
  • chimeric polypeptides of the present invention may be produced using a combination of both automated peptide synthesis and recombinant techniques.
  • a chimeric polypeptide of the present invention may contain a combination of modifications including deletion, substitution, insertion and derivatization by PEGylation (or other moiety, e.g. polymer, fatty acyl chain, C-terminal amidation).
  • PEGylation or other moiety, e.g. polymer, fatty acyl chain, C-terminal amidation.
  • Such a chimeric polypeptide may be produced in stages. In the first stage, an intermediate chimeric polypeptide containing the modifications of deletion, substitution, insertion, and any combination thereof, may be produced by recombinant techniques as described.
  • the intermediate chimeric polypeptide is PEGylated (or subjected to other chemical derivatization, e.g., acylation, C-terminal amidation) through chemical modification with an appropriate PEGylating reagent (e.g., from NeKtar Transforming Therapeutics, San Carlos, Calif.) to yield the desired chimeric polypeptide derivative.
  • an appropriate PEGylating reagent e.g., from NeKtar Transforming Therapeutics, San Carlos, Calif.
  • Peptides may be purified by any number of methods known in the art, including as described herein In one method peptides are purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10 ⁇ , 2.2 ⁇ 25 cm; Vydac, Hesperia, Calif.) may be used to isolate peptides, and purity may be determined using a C4, C8 or C18 analytical column (5 ⁇ , 0.46 ⁇ 25 cm; Vydac).
  • Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program.
  • Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115° C., 20-24 h). Hydrolysates may be derivatized and analyzed by standard methods (Cohen et al, T HE P ICO T AG M ETHOD : A M ANUAL OF A DVANCED T ECHNIQUES FOR A MINO A CID A NALYSIS , pp.
  • Methods are available for assaying the level of protein expression by a host cell. Procedures useful for assaying the level of protein expression by a host cell are exemplified in the following typical protocol. About 25 ⁇ A BL21 E. coli cells are transformed with 2 ul plasmid DNA (expression vector for the chimeric polynucleotide). Cells can be plated and incubated overnight at 37 degrees C. or at room temperature (RT) over a 48-hr period. A single colony can be selected and used to grow starter culture in 4 ml LB media with appropriate antibiotic for ⁇ 6 hrs.
  • RT room temperature
  • Glycerol stocks can be prepared by adding 100 ul 80% sterile glycerol to 900 ul stock, which can then be mixed gently and stored at ⁇ 80 C. A 250 ⁇ l sample can be removed for TCP uninduced sample. An aliquot, for example, 2 ml of Magic media containing appropriate antibiotic can be inoculated with 5 ⁇ l starter culture, which can then be incubated overnight (up to 24 hrs) at 37 C, 300 rpm. As known in the art, Magic Media is autoinducing.
  • 60 ml Magic Media containing appropriate antibiotic can be inoculated with 60 ⁇ l starter culture in a 250 ml or 125 ml Thompson flask, which can then be incubated overnight (up to 24 hrs) at 30 C, 300 rpm. After incubation, 250 ⁇ l culture can be removed from each tube and the cells pelleted. The cell can be resuspended in 1 ml 50 mM Tris pH 8, 150 mM NaCl, to which can be added 0.1 volumes (100 ul) POP culture reagent and 1 ⁇ l r-lysozyme (1:750 dilution in r-lysozyme buffer). The mixture can be mixed well and incubated at least 10 min at RT.
  • the preparation can then be centrifuged 10 min at 14000 ⁇ G.
  • the supernatant (soluble fraction) can be removed and retained, and samples can be prepared for gel analysis (15 ⁇ l+5 ⁇ l LDS).
  • the remaining inclusion body pellet can be resuspended in 1 ml 1% SDS with sonication.
  • the sample can be prepared for gel analysis (15 ul+5 ⁇ l LDS).
  • 1.0 volumes POP culture reagent and 1 ⁇ l r-lysozyme (1:750 dilution in r-lysozyme buffer) can be added.
  • the mixture can be mixed well and incubated at least 10 min at RT. These samples may not need to be centrifuged.
  • the sample can then be prepared for gel analysis (15 ⁇ l+5 ⁇ l LDS).
  • NU-PAGE gels (4-12%) non-reduced in 1 ⁇ MES buffer can be run and stained with SimplyBlue microwave protocol. Destaining can be conducted overnight, as known in the art. A gel image can be retained, and analyzed to determine protein expression levels.
  • the cell pellet can be resuspended in a minimum of 100 ml Lysis buffer for each 50 ml culture. Upon the addition of 30 ml, a 10 ml pipette can be used to resuspend, then the tube can be washed out with an additional 70 ml.
  • the resuspended cell solution can be multiply run, e.g., 4 passes, through a microfluidizer at 100 PSI (min) taking care to keep chamber in ice water through the entire process.
  • the fluidized slurry can be centrifuged at 14000 ⁇ g, 20 min (e.g., JLA 10.5, 10,000 rpm, using 250 ml Nalgene® bottles).
  • the inclusion body pellet can be resuspended on ice in chilled lysis buffer with stir bar and stir plate for 1 hour at 4 C after disruption with pipette tip.
  • the pellet can be resuspended a second time in distilled H 2 O with stir bar and stir plate for 1 hour at 4 C after disruption with pipette tip, followed by centrifugation at 14000 ⁇ g, 15 min.
  • the supernatant can be removed and discarded.
  • the resultant can be stored at ⁇ 80 C.
  • Inclusion body pellets can be solubilized in appropriate volume of solubilization buffer (8M urea or 8M guanidine, 50 mM Tris, 10 mM DTT, pH 7.75) for 1 hour at RT.
  • solubilized pellets can be centrifuged for 20 min at 27 000 g.
  • Filtered (e.g., 0.4 um) supernatant can be transferred drop by drop into appropriate volume of refolding buffer (50 mM Tris-HCl, 1 M urea, 0.8 M arginine, 4 mM cysteine, 1 mM cystamine; pH 8) at RT.
  • Samples can be concentrated and run on a gel filtration column (SuperdexTM 75 26/60) at 1-2 ml/min in 4 C environment using a GE Healthsciences AKTAFPLCTM. Appropriate protein containing fractions can be identified via SDS-PAGE, pooled and run through a second gel filtration column. Pooled protein can then be concentrated in Amicon filter to appropriate concentration and assayed for endotoxin levels using, e.g., Endosafe® PTS Reader (Charles River), as known in the art.
  • a protein sample Once a protein sample has passed the endotoxin criteria, it can be sterile filtered, dispensed into aliquots and run through quality control assays.
  • Quality control assays can include analytical HPLC-SEC, non reducing SDS PAGE and RP HPLC-MS to obtain approximate mass. Proteins can be obtained in 1 ⁇ PBS (137 mM sodium chloride, 2.7 mM potassium chloride, 4.3 mM disodium phosphate, 1.4 mM monopotassium phosphate, pH7.2), distributed into aliquots and flash frozen for storage at ⁇ 70 to ⁇ 80° C.
  • Obesity and its associated disorders including overweight are common and serious public health problems in the United States and throughout the world.
  • Upper body obesity is the strongest risk factor known for type 2 diabetes mellitus and is a strong risk factor for cardiovascular disease.
  • Obesity is a recognized risk factor for hypertension, atherosclerosis, congestive heart failure, stroke, gallbladder disease, osteoarthritis, sleep apnea, reproductive disorders such as polycystic ovarian syndrome, cancers of the breast, prostate, and colon, and increased incidence of complications of general anesthesia. See, e.g., Kopelman, 2000 , Nature 404:635-43.
  • Obesity reduces life-span and carries a serious risk of the co-morbidities listed above, as well disorders such as infections, varicose veins, acanthosis nigricans, eczema, exercise intolerance, insulin resistance, hypertension hypercholesterolemia, cholelithiasis, orthopedic injury, and thromboembolic disease. See e.g., Rissanen et al, 1990 , Br. Med. J., 301:835-7. Obesity is also a risk factor for the group of conditions called insulin resistance syndrome, or “Syndrome X” and metabolic syndrome. The worldwide medical cost of obesity and associated disorders is enormous.
  • the pathogenesis of obesity is believed to be multi-factoral.
  • a problem is that, in obese subjects, nutrient availability and energy expenditure do not come into balance until there is excess adipose tissue.
  • the central nervous system (CNS) controls energy balance and coordinates a variety of behavioral, autonomic and endocrine activities appropriate to the metabolic status of the animal.
  • the mechanisms or systems that control these activities are broadly distributed across the forebrain (e.g., hypothalamus), hindbrain (e.g., brainstem), and spinal cord.
  • metabolic (i.e., fuel availability) and cognitive (i.e., learned preferences) information from these systems is integrated and the decision to engage in appetitive (food seeking) and consummatory (ingestion) behaviors is either turned on (meal procurement and initiation) or turned off (meal termination).
  • the hypothalamus is thought to be principally responsible for integrating these signals and then issuing commands to the brainstem.
  • Brainstem nuclei that control the elements of the consummatory motor control system e.g., muscles responsible for chewing and swallowing.
  • these CNS nuclei have literally been referred to as constituting the “final common pathway” for ingestive behavior.
  • CNS-directed anti-obesity therapeutics e.g., small molecules and peptides
  • Obesity remains a poorly treatable, chronic, essentially intractable metabolic disorder. Accordingly, a need exists for new therapies useful in weight reduction and/or weight maintenance in a subject. Such therapies would lead to a profound beneficial effect on the subject's health. Methods and therapies employing the chimeric peptides disclosed herein, either alone or in combination with other anti-obesity agents (see, e.g., WO 2009064298 and US 20080207512) may provide such beneficial effects.
  • Leptin deficiency has been shown to result in obesity.
  • leptin deficiency is congenital leptin deficiency, a rare genetic disorder. See Montague et al., 1997 , Nature 387: 903-908.
  • Severe leptin deficiency can be a result of uncontrolled insulin-deficient diabetes mellitus that results from destruction of insulin-secreting ⁇ -cells. It is theorized that the lack of insulin leads to synthesis and storage of triglycerides in adipose tissue, which prevents weight gain and in turn dramatically reduces plasma leptin levels since leptin is synthesized in adipose tissue.
  • Leptin deficiencies can be treated with leptin replacement therapy, such as via daily leptin or leptin agonist injections.
  • leptin replacement therapy such as via daily leptin or leptin agonist injections.
  • the chimeric polypeptides described herein can provide a more convenient and advantageous therapeutic treatment of such diseases and disorders.
  • Diabetes mellitus is recognized as a complex, chronic disease in which 60% to 70% of all case fatalities among diabetic patients are a result of cardiovascular complications. Diabetes is not only considered a coronary heart disease risk equivalent but is also identified as an independent predictor of adverse events, including recurrent myocardial infarction, congestive heart failure, and death following a cardiovascular incident. The adoption of tighter glucose control and aggressive treatment for cardiovascular risk factors would be expected to reduce the risk of coronary heart disease complications and improve overall survival among diabetic patients. Yet, diabetic patients are two to three times more likely to experience an acute myocardial infarction than non-diabetic patients, and diabetic patients live eight to thirteen years less than non-diabetic patients.
  • ACC/AHA American College of Cardiology/American Heart Association
  • ACS American College of Cardiology/American Heart Association
  • ACS glucose-lowering therapy for hospitalized diabetic/ACS patients should be targeted to achieve preprandial glucose less than 10 mg/dL, a maximum daily target than 180 mg/dL, and a post-discharge hemoglobin A1c less than 7%.
  • leptin can have direct benefit to treating diabetes, particularly in type I diabetes and type II diabetes, with or without the presence of obesity, and more particularly in conditions of low serum leptin. It has been reported that leptin replenishment reduced or prevented hyperinsulinemia, insulin resistance and hyperglycemia in various animal models of diabetes type 1 and 2 with or without attendant obesity. For example, high leptin plasma levels generated either by pharmacological administration of leptin or with adenoviral gene therapy reduced hyperglycemia and associated increases of plasma glucagon levels in STZ-induced diabetes, despite persistently low insulin levels.
  • lipodystrophy is characterized by abnormal or degenerative conditions of the body's adipose tissue.
  • Dyslipidemia is a disruption in the normal lipid component in the blood. It is believed that prolonged elevation of insulin levels can lead to dyslipidemia.
  • Hyperlipidemia is the presence of raised or abnormal levels of lipids and/or lipoproteins in the blood.
  • Hypothalamic amenorrhea is a condition in which menstruation stops for several months due to a problem involving the hypothalamus. It has been found that leptin replacement therapy in women with hypothalamic amenorrhea improves reproductive, thyroid, and growth hormone axes and markers of bone formation without causing adverse effects.
  • Fatty liver disease e.g., nonalcoholic fatty liver disease (NAFLD) refers to a wide spectrum of liver disease ranging from simple fatty liver (steatosis), to nonalcoholic steatohepatitis (NASH), to cirrhosis (irreversible, advanced scarring of the liver). All of the stages of NAFLD have in common the accumulation of fat (fatty infiltration) in the liver cells (hepatocytes). It is believed that leptin is one of the key regulators for inflammation and progression of fibrosis in various chronic liver diseases including NASH. See e.g., Ikejima et al., Hepatology Res. 33:151-154.
  • AD Alzheimer's disease
  • AD Alzheimer's disease
  • brain lipids are intricately involved in A-beta-related pathogenic pathways, and that an important modulator of lipid homeostasis is leptin.
  • leptin can modulate bidirectional A-beta kinesis, reducing its levels extracellularly.
  • chronic administration of leptin to AD-transgenic animals reduced the brain A-beta load, underlying its therapeutic potential. See Fewlass et al., 2004 , FASEB J., 18:1870-1878.
  • type 2 diabetes mellitus and AD share epidemiological and biochemical features in that both are characterized by insoluble protein aggregates with a fibrillar conformation—amylin in type 2 DM pancreatic islets, and A ⁇ in AD brain. Without wishing to be bound by any theory, it is believed that similar toxic mechanisms may characterize type-2 DM and AD. See Lim et al., FEBS Lett., 582:2188-2194.
  • Metabolic Syndrome X is characterized by insulin resistance, dyslipidemia, hypertension, and visceral distribution of adipose tissue, and plays a pivotal role in the pathophysiology of type 2 diabetes. It has also been found to be strongly correlated with NASH, fibrosis, and cirrhosis of the liver. Accordingly, chimeric polypeptides described herein can be useful in the treatment of metabolic syndrome X.
  • Huntington's Disease is an autosomal dominant, neurogenerative disease.
  • Features of the disease include motor disturbances, dementia, psychiatric problems, and unintended weight loss.
  • Chimeric polypeptides described herein can be useful in the treatment of Huntington's Disease.
  • a method for treating a disease or disorder in a subject is in need of treatment for the disease or disorder.
  • the disease or disorder can be lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II).
  • Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
  • the method of treatment includes administration to the subject of a chimeric polypeptide as described herein in an amount effective to treatment the disease or disorder.
  • in vitro assays e.g., receptor assays
  • in vitro assays are useful as a screening strategy for potential metabolic agents, such as described herein.
  • a variety of in vitro assays are known in the art, including those described as follows.
  • Leptin binding can be measured by the potency of a test compound in displacing 125 I-recombinant-Leptin (murine) from the surface membrane expressing chimeric Leptin (Hu)-EPO (Mu) receptor presented by the 32D OBECA cell line ( J Biol Chem 1998; 273(29): 18365-18373).
  • Purified cell membranes can be prepared by homogenization from harvested confluent cell cultures of 32D OBECA cells. Membranes can be incubated with 1251 -rec-Murine-Leptin and increasing concentrations of test compound for 3 hours at ambient temperature in 96-well polystyrene plates.
  • Bound and unbound ligand fractions can then be separated by rapid filtration onto 96-well GF/B plates pre-blocked for at least 60′ in 0.5% PEI (polyethyleneimine). Glass fiber plates can then be dried, scintillant added, and CPM determined by reading on a multiwell scintillation counter capable of reading radiolabeled iodine.
  • PEI polyethyleneimine
  • Increased levels of phosphorylated STATS can be measured following treatment of 32D-Keptin cells ectopically expressing chimeric Hu-Leptin/Mu-EPO receptor with a test compound.
  • the 32D-Keptin cells (identical to 32D-OBECA cells but maintained in culture with leptin) can be leptin weaned overnight and then treated with test compounds in 96-well plates for 30 minutes at 37° C. followed by cell extraction.
  • the pSTAT5 levels in the cell lysates can be determined using the Perkin Elmer AlphaScreen® SureFire® pSTAT5 assay kit in a 384-well format (PROXIPLATETM 384 Plus).
  • the efficacy of test compounds can be determined relative to the maximal signal in cell lysates from cells treated with Human leptin.
  • compositions comprising compounds described herein in combination with a pharmaceutically acceptable excipient (e.g., carrier).
  • pharmaceutically acceptable carrier refers to pharmaceutical excipients, for example, pharmaceutically, physiologically, acceptable organic or inorganic carrier substances suitable for enteral or parenteral application that do not deleteriously react with the active agent.
  • suitable pharmaceutically acceptable carriers include water, salt solutions (e.g., Ringer's solution and the like), alcohols, oils, gelatins, and carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, and polyvinyl pyrrolidine.
  • Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • the chimeric polypeptides described herein can be administered alone or can be co-administered to a subject. Co-administration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). For example, it has been found that obesity can be beneficially treated with a combination therapy including a leptin (e.g., metreleptin) and certain other anti-obesity compounds. See e.g., U.S. Published Appl. No. 2008/0207512. Accordingly, a chimeric polypeptide described herein could be useful for treatment of obesity.
  • a leptin e.g., metreleptin
  • certain other anti-obesity compounds See e.g., U.S. Published Appl. No. 2008/0207512. Accordingly, a chimeric polypeptide described herein could be useful for treatment of obesity.
  • the formulations and methods described herein further provide that the chimeric polypeptide is co-administered with one or more anti-diabetic agents, such as anti-hyperglycemia agents, e.g. insulin, amylins, pramlintide, metformin.
  • anti-diabetic agents such as anti-hyperglycemia agents, e.g. insulin, amylins, pramlintide, metformin.
  • the formulations and methods described herein further provide that the chimeric polypeptide is co-administered with one or more cholesterol and/or triglyceride lowering agents.
  • exemplary agents include HMG CoA reductase inhibitors (e.g., atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin); bile ace sequestrants (e.g., colesevelam, cholestyramine, colestipol); fibrates (e.g., fenofibrate, clofibrate, gemfibrozil); ezetimibe, nicotinic acid, probucol, a lovastatin/niacin combination; an atorvastatin/amlodipine combination; and a simvastatin/ezetimibe combination.
  • HMG CoA reductase inhibitors e.g., atorvastatin, fluvastatin,
  • the individual chimeric polypeptides can be co-administered with other anti-obesity agents, such as exenatide or liraglutide.
  • compositions for use as a medicament, i.e. for use in therapy, since the leptin compound is a therapeutically active compound.
  • Compositions comprising a chimeric polypeptide, either liquid or dry form, and optionally at least one pharmaceutically acceptable carrier and/or excipient are also specifically contemplated and are exemplified herein.
  • Co-administration can be achieved by separately administering the chimeric polypeptide with the second agent, or by administering a single pharmaceutical formulation comprising the chimeric polypeptide and the second agent.
  • Appropriate dosage regimens for the second agents are generally known in the art.
  • the preparations can also be co-administered, when desired, with other active substances (e.g. to reduce metabolic degradation) as known in the art or other therapeutically active agents.
  • other active substances e.g. to reduce metabolic degradation
  • Amylin is a peptide hormone synthesized by pancreatic ⁇ -cells that is co-secreted with insulin in response to nutrient intake.
  • the sequence of amylin is highly preserved across mammalian species, with structural similarities to calcitonin gene-related peptide (CGRP), the calcitonins, the intermedins, and adrenomedullin, as known in the art.
  • CGRP calcitonin gene-related peptide
  • the glucoregulatory actions of amylin complement those of insulin by regulating the rate of glucose appearance in the circulation via suppression of nutrient-stimulated glucagon secretion and slowing gastric emptying.
  • pramlintide a synthetic and equipotent analogue of human amylin, reduces postprandial glucose excursions by suppressing inappropriately elevated postprandial glucagon secretion and slowing gastric emptying.
  • sequences of rat amylin, human amylin and pramlintide follow:
  • rat amylin (SEQ ID NO: 86) KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY; human amylin: (SEQ ID NO: 87) KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY; Pramlintide: (SEQ ID NO: 88) KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY.
  • Davalintide also known as “AC-2307” is a potent amylin agonist useful in the treatment of a variety of disease indications. See WO 2006/083254 and WO 2007/114838, each of which is incorporated by reference herein in its entirety and for all purposes.
  • Davalintide is a chimeric peptide, having an N-terminal loop region of amylin or calcitonin and analogs thereof, an alpha-helical region of at least a portion of an alpha-helical region of calcitonin or analogs thereof or an alpha-helical region having a portion of an amylin alpha-helical region and a calcitonin alpha-helical region or analog thereof, and a C-terminal tail region of amylin or calcitonin.
  • the sequences of human calcitonin, salmon calcitonin and davalintide follow:
  • human calcitonin (SEQ ID NO: 89) CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP; salmon calcitonin: (SEQ ID NO: 90) CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP; davalintide: (SEQ ID NO: 91) KCNTATCVLGRLSQELHRLQTYPRTNTGSNTY.
  • amylins and davalintide, and fragments and analogs thereof can require C-terminal amidation to elicit a full biological response. It is understood that amylin compounds such as those described herein which include amylins and/or davalintide, and fragment and analogs thereof, can be amidated at the C-terminal.
  • Amylin agonist compounds include native amylin peptides, amylin analog peptides, and other compounds (e.g., small molecules) that have amylin agonist activity.
  • the “amylin agonist compounds” can be derived from natural sources, can be synthetic, or can be derived from recombinant DNA techniques.
  • Amylin agonist compounds have amylin agonist receptor binding activity and may comprise amino acids (e.g., natural, unnatural, or a combination thereof), peptide mimetics, chemical moieties, and the like. The skilled artisan will recognize amylin agonist compounds using amylin receptor binding assays or by measuring amylin agonist activity in soleus muscle assays.
  • amylin agonist compounds will have an IC 50 of about 200 nM or less, about 100 nM or less, or about 50 nM or less, in an amylin receptor binding assay, such as that described herein, in U.S. Pat. No. 5,686,411, and US Publication No. 2008/0176804, the disclosures of which are incorporated by reference herein in their entireties and for all purposes.
  • amylin agonist compounds will have an EC 50 of about 20 nM or less, about 15 nM or less, about 10 nM or less, or about 5 nM or less in a soleus muscle assay, such as that described herein and in U.S. Pat. No. 5,686,411.
  • the amylin agonist compound has at least 90% or 100% sequence identity to 25,28,29 Pro-human-amylin.
  • the amylin agonist compound is a peptide chimera of amylin (e.g., human amylin, rat amylin, and the like) and calcitonin (e.g., human calcitonin, salmon calcitonin, and the like).
  • calcitonin e.g., human calcitonin, salmon calcitonin, and the like.
  • Suitable and exemplary amylin agonist compounds are also described in US Publication No. 2008/0274952, the disclosure of which is incorporated by reference herein in its entirety and for all purposes.
  • amylin analog as used herein is meant an amylin agonist that has at least 50% sequence identity, preferably at least 70% sequence identity, to a naturally-occurring form of amylin, either rat or human or from any other species, and is derived from them by modifications including insertions, substitutions, extensions, and/or deletions of the reference amino acid sequence.
  • the amylin analog sequence can have at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 95% amino acid sequence identity with the reference amylin.
  • the analog has 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or even 16 amino acid substitutions, insertions, extensions, and/or deletions relative to the reference compound.
  • the amylin analog may comprise conservative or non-conservative amino acid substitutions (including non-natural amino acids and L and D forms). These analogs are preferably peptides, peptide derivatives or peptide mimics.
  • Typical amylin analogs will be peptides, especially of 32-37 amino acids, e.g. 27 to 45, especially 28 to 38, and even 31-36.
  • Amylin analogs with identity to rat and human amylin include 25,28,29 Pro-h-amylin (pramlintide) (SEQ ID NO: 88); des- 1 Lys-h-amylin (SEQ ID NO: 111); 25 Pro, 26 Val, 28,29 Pro-h-amylin (SEQ ID NO: 112); 18 Arg, 25,28 Pro-h-amylin (SEQ ID NO: 113); des- 1 L-h amylin (SEQ ID NO: 114); 18 Arg, 25,28,29 pro-h-amylin (SEQ ID NO: 115); des- 1 Lys, 18 Arg, 25,28,29 Pro-h-amylin (SEQ ID NO: 116); des- 1 ,Lys 25,28,29 Pro-h-amylin (SEQ ID NO: 117); 25 Pro, 26 Val, 28,29 Pro-h-amylin (SEQ ID NO: 118); 28 Pro-h-amylin,
  • Amylin analogs include amino acid sequences of residues 1-37 of Formula (I) following, wherein up to 25% of the amino acids set forth in Formula (I) may be deleted or substituted with a different amino acid:
  • X′ is hydrogen, an N-terminal capping group, or a linker to a duration enhancing moiety.
  • Xaa 1 is Lys or a bond
  • Xaa 21 is Lys, Cys, or Asn
  • Xaa 24 is Lys, Cys, or Gly
  • Xaa 25 is Lys, Cys, or Pro
  • Xaa 26 is Lys, Cys, or Ile
  • Xaa 27 is Lys, Cys, or Leu
  • Xaa 28 is Lys, Cys, or Pro
  • Xaa 29 is Lys, Cys, or Pro
  • Xaa 31 is Lys, Cys, or Asn.
  • variable X represents a C-terminal functionality (e.g., a C-terminal cap).
  • X is substituted or unsubstituted amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted cycloalkylamino, substituted or unsubstituted arylamino, substituted or unsubstituted aralkylamino, substituted or unsubstituted alkyloxy, substituted or unsubstituted aryloxy, substituted or unsubstituted aralkyloxy, or hydroxyl.
  • X is preferably amine thereby forming a C-terminal amide.
  • up to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or even 50% of the amino acids of residues 1-37 of Formula (I) are deleted or substituted in a polypeptide component according to Formula (I).
  • the amylin analog component has 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or even 16 amino acid substitutions relative to the amino acid sequence set forth in Formula (I).
  • the amylin analog has a sequence which has a defined sequence identity with respect to the residues 1-37 of the amino acid sequence according to Formula (I).
  • the sequence identity between an amylin analog described herein and residues 1-37 of Formula (I) is 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or even higher.
  • up to 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or even less of the amino acids set forth in residues 1-37 of Formula (I) may be deleted or substituted with a different amino acid.
  • the sequence identity is within the range 75%-100%.
  • sequence identity is within the range 75%-90%. In some embodiments, the sequence identity is within the range 80%-90%. In some embodiments, the sequence identity is at least 75%. In some embodiments, the amylin analog has the sequence of residues 1-37 of Formula (I).
  • amylin analogs including those of Formula (I), form the basis of a polypeptide component to which one or more duration enhancing moieties are linked, optionally through a linker, to form an amylin polypeptide conjugate.
  • the polypeptide component serves as a template (“polypeptide template”) to which is attached, preferably by covalent attachment, one or more duration enhancing moieties.
  • Linkage of the duration enhancing moiety to the polypeptide component can be through a linker as described herein.
  • linkage of the duration enhancing moiety to the polypeptide component can be via a direct covalent bond.
  • the duration enhancing moiety can be a water soluble polymer as described herein.
  • a plurality of duration enhancing moieties are attached to the polypeptide component, in which case each linker to each duration enhancing moiety is independently selected from the linkers described herein.
  • Amylin analogs useful as polypeptide components described herein include, but are not limited to, the compounds set forth in residues 1-37 of Formula (I) provided in Table 1 below. Unless indicated to the contrary, all peptides described herein, including peptides having an expressly provided sequence, are contemplated in both free carboxylate and amidated forms.
  • linker in the context of attachment of duration enhancing moieties to a polypeptide component in an amylin polypeptide conjugate described herein, means a divalent species (-L-) covalently bonded in turn to a polypeptide component having a valency available for bonding and to a duration enhancing moiety having a valency available for bonding.
  • the available bonding site on the polypeptide component is conveniently a side chain residue (e.g., lysine, cysteine, aspartic acid, and homologs thereof).
  • the available bonding site on the polypeptide component is the side chain of a lysine or a cysteine residue.
  • the available bonding site on the polypeptide component is the N-terminal amine. In some embodiments, the available bonding site on the polypeptide component is the C-terminal carboxyl. In some embodiments, the available bonding site on the polypeptide component is a backbone atom thereof.
  • linking amino acid residue means an amino acid within residues 1-37 of Formula (I) to which a duration enhancing moiety is attached, optionally through a linker.
  • compounds are provided having a linker covalently linking a polypeptide component with a duration enhancing moiety.
  • the linker is optional; i.e., any linker may simply be a bond.
  • the linker is attached at a side chain of the polypeptide component.
  • the linker is attached to a backbone atom of the polypeptide component.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and an amino acid residue in position 2 to 37 has been substituted with a lysine residue or cysteine residue and wherein said lysine residue or cysteine residue is linked to a polyethylene glycol polymer, optionally via a linker, wherein the amino acid numbering conforms with the amino acid number in SEQ ID NO:88.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in any one of position 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 31, 32, 33, 34, 35, 36, or 37 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in any one of position 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 31, 32, 33, 34, 35, 36, or 37 is substituted with a lysine residue and wherein
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in any one of position 21, 24-29, or 31 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in any one of position 21, 24-29, or 31 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 21 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 21 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 24 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 24 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 25 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 25 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 26 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 26 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 27 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 27 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 28 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 28 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 29 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 29 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the invention relates to an amylin polypeptide conjugate, which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 31 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • an amylin polypeptide conjugate which is a derivative of pramlintide with SEQ ID NO:88 or an analog thereof, wherein the amino acid residue in position 1 is absent (i.e., des-Lys 1 ) and wherein an amino acid residue in position 31 is substituted with a lysine residue and wherein said lysine residue is linked to a polyethylene glycol polymer, optionally via a linker.
  • the duration enhancing moiety is a water-soluble polymer.
  • a “water soluble polymer” means a polymer which is sufficiently soluble in water under physiologic conditions of e.g., temperature, ionic concentration and the like, as known in the art, to be useful for the methods described herein.
  • a water soluble polymer can increase the solubility of a peptide or other biomolecule to which such water soluble polymer is attached. Indeed, such attachment has been proposed as a means for improving the circulating life, water solubility and/or antigenicity of administered proteins, in vivo. See e.g., U.S. Pat. No. 4,179,337; U.S. Published Appl. No. 2008/0032408.
  • water-soluble polymers and attachment chemistries have been used towards this goal, such as polyethylene glycol, copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and the like.
  • the linked duration enhancing moiety includes a polyethylene glycol.
  • Polyethylene glycol (“PEG”) has been used in efforts to obtain therapeutically usable polypeptides. See e.g., Zalipsky, S., 1995 , Bioconjugate Chemistry, 6:150-165; Mehvar, R., 2000 , J. Pharm. Pharmaceut. Sci., 3:125-136.
  • PEG backbone [(CH 2 CH 2 —O—) n , n: number of repeating monomers] is flexible and amphiphilic.
  • the long, chain-like PEG molecule or moiety is believed to be heavily hydrated and in rapid motion when in an aqueous medium. This rapid motion is believed to cause the PEG to sweep out a large volume and prevents the approach and interference of other molecules.
  • PEG polymer chains can protect such chemical entity from immune response and other clearance mechanisms.
  • pegylation can lead to improved drug efficacy and safety by optimizing pharmacokinetics, increasing bioavailability, and decreasing immunogenicity and dosing frequency.
  • “Pegylation” refers in the customary sense to conjugation of a PEG moiety with another compound.
  • PEG polyethylene glycol polymer
  • mPEG methoxy-PEG
  • attachment sites in proteins include primary amino groups, such as those on lysine residues or at the N-terminus, thiol groups, such as those on cysteine side-chains, and carboxyl groups, such as those on glutamate or aspartate residues or at the C-terminus. Common sites of attachment are to the sugar residues of glycoproteins, cysteines or to the N-terminus and lysines of the target polypeptide.
  • pegylated and the like refer to covalent attachment of polyethylene glycol to a polypeptide or other biomolecule, optionally through a linker as described herein and/or as known in the art.
  • a PEG moiety in an amylin polypeptide conjugate described herein has a nominal molecular weight within a specified range.
  • the size of a PEG moiety is indicated by reference to the nominal molecular weight, typically provided in kilodaltons (kD).
  • the molecular weight is calculated in a variety of ways known in the art, including number, weight, viscosity and “Z” average molecular weight. It is understood that polymers, such as PEG and the like, exist as a distribution of molecule weights about a nominal average value.
  • the term “mPEG40 KD” refers to a methoxy polyethylene glycol polymer having a nominal molecular weight of 40 kilodaltons. Reference to PEGs of other molecular weights follows this convention.
  • the PEG moiety has a nominal molecular weight in the range 10-100 KD, 20-80 KD, 20-60 KD, or 20-40 KD.
  • the PEG moiety has a nominal molecular weight of 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or even 100 KD.
  • the PEG moiety has a molecular weight of 20, 25, 30, 40, 60 or 80 KD.
  • PEG molecules useful for derivatization of polypeptides are typically classified into linear, branched and Warwick (i.e., PolyPEG®) classes of PEGs, as known in the art.
  • the PEG moieties described herein are linear PEGs.
  • the terms “two arm branched,” “Y-shaped” and the like refer to branched PEG moieties, as known in the art.
  • the term “Warwick” in the context of PEGs, also known as “comb” or “comb-type” PEGs refers to a variety of multi-arm PEGs attached to a backbone, typically poly(methacrylate), as known in the art.
  • Cmpd 19 is the result of the conjugation of mPEG40 KD to the N-terminal nitrogen of Cmpd 1.
  • Cmpd 20 is the result of conjugation of mPEG40 KD to the N-terminal nitrogen of Cmpd 2.
  • Standard single letter abbreviations for amino acids can be used, as can standard three-letter abbreviations.
  • Cmpd 24 is an analog of Cmpd 10 wherein the residue at position 26 of Cmpd 9 is substituted for lysine, and the pendant amine functionality of lysine 26 (i.e., K 26 ) is conjugated with a PEG40 KD moiety.
  • exemplary compounds are provided in Table 2 below.
  • the pharmaceutical compounds of the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington's Pharmaceutical Sciences by E. W. Martin. See also Wang et al. (1988) J. of Parenteral Sci . and Tech., Technical Report No. 10, Supp. 42:2 S.
  • the chimeric polypeptides may be formulated into a stable, safe pharmaceutical composition for administration to a patient.
  • Pharmaceutical formulations contemplated for use in the methods of the invention may comprise approximately 0.01 to 1.0% (w/v), in certain cases 0.05 to 1.0%, of the chimeric polypeptide, approximately 0.02 to 0.5% (w/v) of an acetate, phosphate, citrate or glutamate buffer allowing a pH of the final composition of from about 3.0 to about 7.0; approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol tonicifier and, optionally, approximately 0.005 to 1.0% (w/v) of a preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl, propyl and butyl parabens and phenol. Such a preservative is generally included if the formulated peptide is to be included in a multiple use product.
  • a pharmaceutical formulation of the present chimeric polypeptides may contain a range of concentrations of the compound(s), e.g., between about 0.01% to about 98% w/w, or between about 1 to about 98% w/w, or preferably between 80% and 90% w/w, or preferably between about 0.01% to about 50% w/w, or more preferably between about 10% to about 25% w/w in these embodiments.
  • a sufficient amount of water for injection may be used to obtain the desired concentration of solution.
  • Additional tonicifying agents such as sodium chloride, as well as other known excipients, may also be present, if desired. In some cases, such excipients are useful in maintenance of the overall tonicity of the compound.
  • An excipient may be included in the presently described formulations at various concentrations. For example, an excipient may be included in the concentration range from about 0.02% to about 20% w/w, preferably between about 0.02% and 0.5% w/w, about 0.02% to about 10% w/v, or about 1% to about 20% w/w.
  • an excipient may be included in solid (including powdered), liquid, semi-solid or gel form.
  • the pharmaceutical formulations may be composed in various forms, e.g., solid, liquid, semisolid or liquid.
  • solid as used herein, is meant to encompass all normal uses of this term including, for example, powders and lyophilized formulations.
  • the presently described formulations may be lyophilized.
  • buffer when used with reference to hydrogen-ion concentration or pH, refer to the ability of a system, particularly an aqueous solution, to resist a change of pH on adding acid or alkali, or on dilution with a solvent.
  • An example of the former system is acetic acid and sodium acetate.
  • the change of pH is slight as long as the amount of hydronium or hydroxyl ion added does not exceed the capacity of the buffer system to neutralize it.
  • liquid vehicles are suitable for use in the formulations of chimeric polypeptides, for example, water or an aqueous/organic solvent mixture or suspension.
  • the stability of a chimeric polypeptide formulation for use as described herein is enhanced by maintaining the pH of the formulation in a range determined by methods known in the art.
  • the pH of the formulation is maintained in the range of about 3.5 to 5.0, or about 3.5 to 6.5, in some embodiments from about 3.7 to 4.3, or about 3.8 to 4.2.
  • pH may be about 4.0, about 5.0, about 6.0, about 7.0, about 8.0, about 9.0, or even higher.
  • pH may be in the physiological range, pH 6-8, preferably pH 7-7.6.
  • the buffer with the chimeric polypeptide is an acetate buffer (preferably at a final formulation concentration of from about 1-5 to about 60 mM), phosphate buffer (preferably at a final formulation concentration of from about 1-5 to about to about 30 mM) or glutamate buffer (preferably at a final formulation concentration of from about 1-5 to about to about 60 mM).
  • the buffer is acetate (preferably at a final formulation concentration of from about 5 to about 30 mM).
  • a stabilizer may be included in the formulations but is not necessarily needed. If included, however, a stabilizer useful in the practice of the present invention is a carbohydrate or a polyhydric alcohol.
  • a suitable stabilizer useful in the practice of the present invention is approximately 1.0 to 10% (w/v) of a carbohydrate or polyhydric alcohol.
  • the polyhydric alcohols and carbohydrates share the same feature in their backbones, i.e., —CHOH—CHOH—, which is responsible for stabilizing the proteins.
  • the polyhydric alcohols include such compounds as sorbitol, mannitol, glycerol, and polyethylene glycols (PEGs). These compounds are straight-chain molecules.
  • the carbohydrates such as mannose, ribose, sucrose, fructose, trehalose, maltose, inositol, and lactose, on the other hand, are cyclic molecules that may contain a keto or aldehyde group. These two classes of compounds have been demonstrated to be effective in stabilizing protein against denaturation caused by elevated temperature and by freeze-thaw or freeze-drying processes.
  • Suitable carbohydrates include: galactose, arabinose, lactose or any other carbohydrate which does not have an adverse affect on a diabetic patient, i.e., the carbohydrate is not metabolized to form unacceptably large concentrations of glucose in the blood.
  • Such carbohydrates are well known in the art as suitable for diabetics.
  • Sucrose and fructose are suitable for use with the compound in non-diabetic applications (e.g. treating obesity).
  • the compound is stabilized with a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, 8000 and even higher).
  • a polyhydric alcohol such as sorbitol, mannitol, inositol, glycerol, xylitol, and polypropylene/ethylene glycol copolymer, as well as various polyethylene glycols (PEG) of molecular weight 200, 400, 1450, 3350, 4000, 6000, 8000 and even higher).
  • PEG polyethylene glycols
  • Another useful feature of the lyophilized formulations of the present invention is the maintenance of the tonicity of the lyophilized formulations described herein with the same formulation component that serves to maintain their stability.
  • USP United States Pharmacopeia
  • anti-microbial agents in bacteriostatic or fungistatic concentrations must be added to preparations contained in multiple dose containers. They must be present in adequate concentration at the time of use to prevent the multiplication of microorganisms inadvertently introduced into the preparation while withdrawing a portion of the contents with a hypodermic needle and syringe, or using other invasive means for delivery, such as pen injectors.
  • Antimicrobial agents should be evaluated to ensure compatibility with all other components of the formula, and their activity should be evaluated in the total formula to ensure that a particular agent that is effective in one formulation is not ineffective in another. It is not uncommon to find that a particular antimicrobial agent will be effective in one formulation but not effective in another formulation.
  • a preservative is, in the common pharmaceutical sense, a substance that prevents or inhibits microbial growth and may be added to pharmaceutical formulations for this purpose to avoid consequent spoilage of the formulation by microorganisms. While the amount of the preservative is not great, it may nevertheless affect the overall stability of the peptide.
  • preservative for use in the pharmaceutical compositions can range from 0.005 to 1.0% (w/v), in some embodiments range for each preservative, alone or in combination with others, is: benzyl alcohol (0.1-1.0%), or m-cresol (0.1-0.6%), or phenol (0.1-0.8%) or combination of methyl (0.05-0.25%) and ethyl or propyl or butyl (0.005%-0.03%) parabens.
  • the parabens are lower alkyl esters of para-hydroxybenzoic acid.
  • Chimeric polypeptides may not have a tendency to adsorb onto the glass in a glass container when in a liquid form, therefore, a surfactant may not be required to further stabilize the pharmaceutical formulation.
  • a surfactant should be used in their formulation. These formulations may then be lyophilized. Surfactants frequently cause denaturation of protein, both of hydrophobic disruption and by salt bridge separation. Relatively low concentrations of surfactant may exert a potent denaturing activity, because of the strong interactions between surfactant moieties and the reactive sites on proteins. However, judicious use of this interaction can stabilize proteins against interfacial or surface denaturation.
  • Surfactants which could further stabilize the chimeric polypeptide may optionally be present in the range of about 0.001 to 0.3% (w/v) of the total formulation and include polysorbate 80 (i.e., polyoxyethylene(20) sorbitan monooleate), CHAPS® (i.e., 3-[(3-cholamidopropyl)dimethylammonio]1-propanesulfonate), Brij® (e.g., Brij® 35, which is (polyoxyethylene (23) lauryl ether), poloxamer, or another non-ionic surfactant.
  • polysorbate 80 i.e., polyoxyethylene(20) sorbitan monooleate
  • CHAPS® i.e., 3-[(3-cholamidopropyl)dimethylammonio]1-propanesulfonate
  • Brij® e.g., Brij® 35, which is (polyoxyethylene (23) lauryl ether), poloxamer, or another non
  • parenteral formulations preferably may be isotonic or substantially isotonic.
  • a preferred vehicle for parenteral products is water.
  • Water of suitable quality for parenteral administration can be prepared either by distillation or by reverse osmosis.
  • Water for injection is the preferred aqueous vehicle for use in the pharmaceutical formulations.
  • Such additional ingredients may include, e.g., wetting agents, emulsifiers, oils, antioxidants, bulking agents, tonicity modifiers, chelating agents, metal ions, oleaginous vehicles, proteins (e.g., human serum albumin, gelatin or proteins) and a zwitterion (e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine).
  • proteins e.g., human serum albumin, gelatin or proteins
  • a zwitterion e.g., an amino acid such as betaine, taurine, arginine, glycine, lysine and histidine.
  • polymer solutions, or mixtures with polymers provide the opportunity for controlled release of the peptide.
  • Such additional ingredients should not adversely affect the overall stability of the pharmaceutical formulation of the present invention.
  • Containers are also an integral part of the formulation of an injection and may be considered a component, for there is no container that is totally inert, or does not in some way affect the liquid it contains, particularly if the liquid is aqueous. Therefore, the selection of a container for a particular injection must be based on a consideration of the composition of the container, as well as of the solution, and the treatment to which it will be subjected. Adsorption of the peptide to the glass surface of the vial can also be minimized, if necessary, by use of borosilicate glass, for example, Wheaton Type I borosilicate glass #33 (Wheaton Type I-33) or its equivalent (Wheaton Glass Co.).
  • borosilicate glass for example, Wheaton Type I borosilicate glass #33 (Wheaton Type I-33) or its equivalent (Wheaton Glass Co.).
  • borosilicate glass vials and cartridges acceptable for manufacture include Kimbel Glass Co., West Co., Bunder Glas GMBH and Form a Vitrum.
  • the biological and chemical properties of the compound may be stabilized by formulation and lyophilization in a Wheaton Type I-33 borosilicate serum vial to a final concentration of 0.1 mg/ml and 10 mg/ml of the compound in the presence of 5% mannitol, and 0.02% Tween 80.
  • each vial is preferably sealed with a rubber stopper closure held in place by an aluminum band.
  • Stoppers for glass vials such as, West 4416/50, 4416/50 (Teflon faced) and 4406/40, Abbott 5139 or any equivalent stopper can be used as the closure for pharmaceutical for injection.
  • these stoppers are compatible with the peptide as well as the other components of the formulation.
  • the peptide can be lyophilized in to vials, syringes or cartridges for subsequent reconstitution.
  • Liquid formulations of the present invention can be filled into one or two chambered cartridges, or one or two chamber syringes.
  • the manufacturing process for the above liquid formulations generally involves compounding, sterile filtration and filling steps.
  • the compounding procedure involves dissolution of ingredients in a specific order (preservative followed by stabilizer/tonicity agents, buffers and peptide) or dissolving at the same time.
  • Typical sterilization processes include filtration, steam (moist heat), dry heat, gases (e.g., ethylene oxide, formaldehyde, chlorine dioxide, propylene oxide, beta-propiolacctone, ozone, chloropicrin, peracetic acid methyl bromide and the like), exposure to a radiation source, and aseptic handling. Filtration is the preferred method of sterilization for liquid formulations of the present invention.
  • the sterile filtration involves filtration through 0.45 um and 0.22 um (1 or 2) which may be connected in series. After filtration, the solution is filled into appropriate vials or containers.
  • the chimeric polypeptides described herein are administered peripherally to the subjects.
  • the liquid pharmaceutical formulations of the present invention are intended for parenteral administration. Suitable routes of administration include intramuscular, intravenous, subcutaneous, intradermal, intraarticular, intrathecal and the like.
  • the subcutaneous route of administration is preferred.
  • mucosal delivery is also preferred. These routes include, but are not limited to, oral, nasal, sublingual, pulmonary and buccal routes which may include administration of the peptide in liquid, semi-solid or solid form.
  • administration via these routes can require substantially more compound to obtain the desired biological effects due to decreased bioavailability compared to parenteral delivery.
  • parenteral controlled release delivery can be achieved by forming polymeric microcapsules, matrices, solutions, implants and devices and administering them parenterally or by surgical means.
  • controlled release formulations are described in U.S. Pat. Nos. 6,368,630, 6,379,704, and 5,766,627, which are incorporated herein by reference. These dosage forms may have a lower bioavailability due to entrapment of some of the peptide in the polymer matrix or device. See e.g., U.S. Pat. Nos. 6,379,704, 6,379,703, and 6,296,842, each of which is incorporated herein by reference in its entirety and for all purposes.
  • the compounds may be provided in dosage unit form containing an amount of the chimeric polypeptide that will be effective in one or multiple doses.
  • an effective amount of the chimeric polypeptide will vary with many factors including the age and weight of the subject, the subject's physical condition, the condition to be treated, and other factors known in the art.
  • An effective amount of the chimeric polypeptides will also vary with the particular combination administered. As described herein, administration of the chimeric polypeptides in combination may allow for a reduced amount of any of the administered chimeric polypeptides to be an effective amount.
  • compositions provided herein include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
  • the actual amount effective for a particular application will depend, inter alia, on the condition being treated.
  • such compositions when administered in methods to treat diabetes, such compositions will contain an amount of active ingredient effective to achieve the desired result (e.g. decreasing fasting blood glucose in a subject).
  • an amount of active ingredient effective to achieve the desired result e.g. decrease the body mass.
  • the dosage and frequency (single or multiple doses) of compound administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g., the disease responsive to compounds described herein); presence of other diseases or other health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen.
  • Other therapeutic regimens or agents can be used in conjunction with the methods and compounds of the invention.
  • Therapeutically effective amounts for use in humans may be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals.
  • the dosage in humans can be adjusted by monitoring one or more physiological parameters, including but not limited to blood sugar and body mass, and adjusting the dosage upwards or downwards, as described above and known in the art.
  • Dosages may be varied depending upon the requirements of the patient and the compound being employed.
  • the dose administered to a patient should be sufficient to affect a beneficial therapeutic response in the patient over time.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side effects.
  • treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
  • the dosage range is 0.001% to 10% w/v. In another embodiment, the dosage range is 0.1% to 5% w/v.
  • typical doses may contain from a lower limit of about 0.1 mg to an upper limit of about 200 mg of the pharmaceutical compound per day. Also contemplated are other dose ranges such as 1 mg to 100 mg of the compound per dose, and 3 mg to 70 mg per dose.
  • the doses per day may be delivered in discrete unit doses, or provided continuously in a 24 hour period or any portion of that the 24 hours.
  • Dosage amounts and intervals can be adjusted individually to provide levels of the administered compound effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.
  • an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicity and yet is entirely effective to treat the clinical symptoms demonstrated by the particular patient.
  • This planning should involve the careful choice of active compound by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent.
  • the ratio between toxicity and therapeutic effect for a particular compound is its therapeutic index and can be expressed as the ratio between LD 50 (the amount of compound lethal in 50% of the population) and ED 50 (the amount of compound effective in 50% of the population).
  • LD 50 the amount of compound lethal in 50% of the population
  • ED 50 the amount of compound effective in 50% of the population.
  • Compounds that exhibit high therapeutic indices are preferred.
  • Therapeutic index data obtained from cell culture assays and/or animal studies can be used in formulating a range of dosages for use in humans.
  • the dosage of such compounds preferably lies within a range of plasma concentrations that include the ED 50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. See, e.g.
  • Protein sequences were designed and back translated using commercial software to DNA sequence for cloning into an E. coli expression vector. Sequences were either obtained as oligonucleotides and stitched together using standard PCR amplification techniques, or they were digested from existing expression constructs using standard restriction enzymes and then ligated back together. Sequences expressing the protein of interest were placed in pET45 with a T7 promoter for inducible expression. After constructs were verified by sequencing, the vector DNA was purified and transformed into an expression host, typically BL21(DE3). A single colony was selected to grow a starter culture in 4 ml LB media for ⁇ 6 hrs.
  • Glycerol stocks were prepared by adding 100 ul 80% glycerol to 900 ul stock and store at ⁇ 80 C. Optionally, 500 ul uninduced sample was retained for gel analysis. A 60 ml culture (magic media) was inoculated using 60 ul starter culture in a 125 ml Thompson flask and incubated @ 30 C overnight. Remove 250 ul sample for analysis. Spin down and freeze cell pellet for later processing.
  • Bacterial cells were harvested and subsequently lysed to isolate inclusion bodies. Since the protein was present in the inclusion bodies, these were solubilized and the protein refolded at 4 C. Proteins were then separated using size exclusion chromatography until only a single band remained and endotoxin levels were acceptable for in vivo testing. Analytical HPLC, RP-LC-MS and SDS-PAGE gel were run as quality control measures on the final protein. Protein was distributed to predetermined aliquots and stored at ⁇ 80 C.
  • chimeric polypeptides described herein have comparable, and some even superior, properties compared with A100 (Compound 37, SEQ ID NO:24). These properties include biological properties such as leptin binding activity, leptin functional activity, and food intake in mice, and pharmaceutical properties such as solubility in neutral pH.
  • Solubility was measured with the following assay: proteins were concentrated at 4 C, spun to remove precipitates, then allowed to equilibrate at room temperature overnight. They were filtered to remove precipitates and then the concentration was determined by measuring absorbance at OD280 and using the theoretical molar extinction coefficient.
  • chimeric polypeptides described herein have comparable, and some even superior, physical stability compared with A100 (Compound 37, SEQ ID NO:24).
  • HPLC reverse phase high performance liquid chromatography
  • UV spectrometry UV spectrometry
  • DLS dynamic light scattering
  • Administered compounds Vehicle (filled circle); Cmpd 41 at 0.1 mg/kg (triangle tip down); Cmpd 41 at 0.3 mg/kg (open diamond); Cmpd 41 at 1 mg/kg (open circle); Cmpd 41 at 3 mg/kg (triangle tip up); Cmpd 41 at 5 mg/kg (star); Cmpd 41 at 10 mg/kg (filled diamond).
  • FIGS. 1A and 1B administration of different doses of the chimeric polypeptide resulted in reduced food intake and body weight relative to the group that received vehicle alone.
  • a dose response is observed in FIG. 1C .
  • Administered compounds Vehicle (filled circle); Cmpd 42 at 0.1 mg/kg (triangle tip up); Cmpd 42 at 0.3 mg/kg (triangle tip up); Cmpd 42 at 1 mg/kg (filled square); Cmpd 42 at 3 mg/kg (bar above and below point); Cmpd 42 at 5 mg/kg (star); Cmpd 42 at 10 mg/kg (bar above point).
  • FIGS. 2A and 2B administration of different doses of the chimeric polypeptide resulted in reduced food intake and body weight relative to the group that received vehicle alone.
  • a dose response is observed in FIG. 2C .
  • the dose responses measured for chimeric polypeptides of the invention are comparable to the dose responses measured for the seal leptin (Cmpd 38) and human leptin (Cmpd 37) from which the chimeric polypeptides are derived.
  • a chimeric polypeptide comprising a wild type seal leptin polypeptide wherein at least one contiguous region of 1-30 amino acids of a wild type seal leptin sequence has been replaced with a contiguous region of 1-30 amino acids of a mature human leptin sequence.
  • a wild type seal leptin sequence comprises the amino acid sequence of SEQ ID NO:28 or SEQ ID NO:31.
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51.
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least one amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least two amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least three amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least four amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least five amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least six amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least seven amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least eight amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least nine amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID
  • a mature human leptin sequence comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51, wherein the mature human leptin sequence has at least ten amino acid sequence selected from the group consisting of: SEQ ID NO:12, SEQ
  • chimeric polypeptide comprises an amino acid sequence with at least 80% identity with an amino acid sequence selected from the group consisting of: SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:
  • chimeric polypeptide of any one of Embodiments 1-16 wherein the chimeric polypeptide comprises an amino acid sequence with at least 80% identity with an amino acid sequence selected from the group consisting of: SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33.
  • chimeric polypeptide of any one of Embodiments 1-17 wherein the chimeric polypeptide comprises an amino acid sequence with at least 80% identity the amino acid sequence of SEQ ID NO:33.
  • chimeric polypeptide of any one of Embodiments 1-20 wherein the chimeric polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33.
  • chimeric polypeptide of any one of Embodiments 1-21 wherein the chimeric polypeptide comprises the amino acid sequence of SEQ ID NO:29.
  • chimeric polypeptide of any one of Embodiments 1-21 wherein the chimeric polypeptide comprises the amino acid sequence of SEQ ID NO:30.
  • chimeric polypeptide of any one of Embodiments 1-21 wherein the chimeric polypeptide comprises the amino acid sequence of SEQ ID NO:32.
  • chimeric polypeptide of any one of Embodiments 1-21 wherein the chimeric polypeptide comprises the amino acid sequence of SEQ ID NO:33.
  • a method for treating a disease or disorder in a subject comprising administering a chimeric polypeptide of any one of Embodiments 1 to 25 to a subject in need thereof in an amount effective to treat said disease or disorder.
  • the disease or disorder is disease or disorder is selected from the group consisting of: lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease, diabetes (including type I and type II), nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
  • the disease or disorder is disease or disorder is selected from the group consisting of: lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease, diabetes (including type I and type II), nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
  • Embodiment 26 or Embodiment 27 wherein the disease or disorder is lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes.
  • a pharmaceutical composition comprising a chimeric polypeptide according to any one of Embodiments 1-25 and a pharmaceutically acceptable excipient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US13/852,521 2010-09-28 2013-03-28 Highly soluble leptins Abandoned US20130203661A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/852,521 US20130203661A1 (en) 2010-09-28 2013-03-28 Highly soluble leptins
US14/703,523 US10087228B2 (en) 2010-09-28 2015-05-04 Chimeric leptin polypeptide and method of using the same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38740210P 2010-09-28 2010-09-28
US42209110P 2010-12-10 2010-12-10
PCT/US2011/053774 WO2012050925A2 (en) 2010-09-28 2011-09-28 Highly soluble leptins
US13/852,521 US20130203661A1 (en) 2010-09-28 2013-03-28 Highly soluble leptins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/053774 Continuation WO2012050925A2 (en) 2010-09-28 2011-09-28 Highly soluble leptins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/703,523 Continuation US10087228B2 (en) 2010-09-28 2015-05-04 Chimeric leptin polypeptide and method of using the same

Publications (1)

Publication Number Publication Date
US20130203661A1 true US20130203661A1 (en) 2013-08-08

Family

ID=45938879

Family Applications (6)

Application Number Title Priority Date Filing Date
US13/852,671 Abandoned US20130274182A1 (en) 2010-09-28 2013-03-28 Engineered polypeptides having enhanced duration of action
US13/852,521 Abandoned US20130203661A1 (en) 2010-09-28 2013-03-28 Highly soluble leptins
US14/703,523 Active US10087228B2 (en) 2010-09-28 2015-05-04 Chimeric leptin polypeptide and method of using the same
US14/800,537 Abandoned US20160137709A1 (en) 2010-09-28 2015-07-15 Engineered polypeptides having enhanced duration of action
US16/751,538 Active US11535659B2 (en) 2010-09-28 2020-01-24 Engineered polypeptides having enhanced duration of action
US18/049,445 Pending US20230115655A1 (en) 2010-09-28 2022-10-25 Engineered polypeptides having enhanced duration of action

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/852,671 Abandoned US20130274182A1 (en) 2010-09-28 2013-03-28 Engineered polypeptides having enhanced duration of action

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/703,523 Active US10087228B2 (en) 2010-09-28 2015-05-04 Chimeric leptin polypeptide and method of using the same
US14/800,537 Abandoned US20160137709A1 (en) 2010-09-28 2015-07-15 Engineered polypeptides having enhanced duration of action
US16/751,538 Active US11535659B2 (en) 2010-09-28 2020-01-24 Engineered polypeptides having enhanced duration of action
US18/049,445 Pending US20230115655A1 (en) 2010-09-28 2022-10-25 Engineered polypeptides having enhanced duration of action

Country Status (14)

Country Link
US (6) US20130274182A1 (hr)
EP (4) EP2621515B1 (hr)
JP (5) JP6174489B2 (hr)
CN (2) CN103403019B (hr)
BR (3) BR122021020041B1 (hr)
CA (3) CA2813038C (hr)
CY (2) CY1119023T1 (hr)
DK (3) DK2621519T3 (hr)
EA (2) EA024507B1 (hr)
ES (3) ES2641869T3 (hr)
MX (2) MX351128B (hr)
PL (1) PL3241558T3 (hr)
PT (2) PT2621515T (hr)
WO (2) WO2012050930A2 (hr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879063B2 (en) 2011-07-08 2018-01-30 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
US11535659B2 (en) 2010-09-28 2022-12-27 Amryt Pharmaceuticals Inc. Engineered polypeptides having enhanced duration of action

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110437321A (zh) 2010-07-09 2019-11-12 阿菲博迪公司 多肽
EP2844269A4 (en) * 2012-03-28 2016-01-06 Amylin Pharmaceuticals Llc TRANSMUCULOUS ADMINISTRATION OF GENETICALLY MODIFIED POLYPEPTIDES
US10155792B2 (en) 2012-09-25 2018-12-18 Affibody Ab Albumin binding polypeptide
US9943568B2 (en) 2013-04-18 2018-04-17 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating cancer
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
EP3038642A4 (en) 2013-08-30 2017-01-18 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
ES2887370T3 (es) 2014-09-04 2021-12-22 Novo Nordisk As Nuevo agonista del receptor de amilina y calcitonina
MX2017004838A (es) 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
US10143726B2 (en) 2014-10-22 2018-12-04 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180020141A (ko) 2015-05-28 2018-02-27 아르모 바이오사이언시스 인코포레이티드 암 치료에 사용되는 peg화된 인터류킨-10
CN113201049B (zh) 2015-08-05 2022-10-04 陕西麦科奥特科技有限公司 有抗凝血和抗血小板活性的多靶点化合物及制法和用途
JP2018527360A (ja) 2015-09-22 2018-09-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 修飾された細胞毒とその治療的使用
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
CN108289924A (zh) 2015-10-02 2018-07-17 哥本哈根大学 阻断组蛋白识别结构域的小分子
BR112019004715A2 (pt) 2016-09-12 2019-07-16 Aegerion Pharmaceuticals Inc métodos para detectar anticorpos neutralizantes anti-leptina
CN110831626B (zh) * 2017-01-30 2024-04-19 亚力兄制药公司 单价抗备解素抗体及抗体片段
US20190314260A1 (en) * 2018-04-13 2019-10-17 Massachusetts Institute Of Technology Engineered treatments for hair repair and long-lasting color retention
WO2023049357A2 (en) * 2021-09-24 2023-03-30 The Uab Research Foundation Control of subunit stoichiometry in single-chain msp nanopores

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756461A (en) * 1995-06-30 1998-05-26 Eli Lilly And Company Methods for treating diabetes

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4572208A (en) 1983-06-29 1986-02-25 Utah Medical Products, Inc. Metabolic gas monitoring apparatus and method
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
FI78231C (fi) 1984-11-21 1989-07-10 Instrumentarium Oy Maetanordning foer metaboliska storheter anslutbar till en respirator.
US4695463A (en) 1985-05-24 1987-09-22 Warner-Lambert Company Delivery system for active ingredients and preparation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
GEP20033145B (en) 1989-10-16 2003-12-25 Amgen Inc Stem Cell Factor
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ATE169031T1 (de) 1991-04-05 1998-08-15 Univ Washington Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
AU4766196A (en) 1995-01-31 1996-08-21 Eli Lilly And Company Anti-obesity proteins
US5563243A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5567678A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5563244A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5569744A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5525705A (en) 1995-01-31 1996-06-11 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
AU4766596A (en) 1995-01-31 1996-08-21 Eli Lilly And Company Ob gene product antibodies
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5574133A (en) 1995-01-31 1996-11-12 Eli Lilly And Company Anti-obesity proteins
US5569743A (en) 1995-01-31 1996-10-29 Eli Lilly And Company Anti-obesity proteins
US5567803A (en) 1995-01-31 1996-10-22 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5594104A (en) 1995-01-31 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5563245A (en) 1995-01-31 1996-10-08 Eli Lilly And Company Anti-obesity proteins
AU4766096A (en) 1995-01-31 1996-08-21 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
EP0736599A3 (en) 1995-04-03 1996-12-11 Takeda Chemical Industries Ltd The rat obesity gene, its gene product and its production
WO1996031526A1 (en) 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
US5614379A (en) 1995-04-26 1997-03-25 Eli Lilly And Company Process for preparing anti-obesity protein
US5840517A (en) * 1995-04-26 1998-11-24 Eli Lilly And Company Process for preparing obesity protein analogs
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
DE741187T1 (de) 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
CA2218529A1 (en) 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity
WO1996037517A1 (en) 1995-05-26 1996-11-28 Eli Lilly And Company Rhesus ob protein and dna
CA2223433C (en) 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
US5581005A (en) 1995-06-16 1996-12-03 The Procter & Gamble Company Method for manufacturing cobalt catalysts
AU6284896A (en) 1995-06-22 1997-01-22 Eli Lilly And Company Obesity protein intermediates and their preparation and use
GB2302559B (en) 1995-06-23 1998-06-03 Draftex Ind Ltd Opening arrangements and methods for closure members
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
ATE259650T1 (de) 1995-08-17 2004-03-15 Amgen Inc Verfahren zur verringerung und zur erhaltung von verringerten blutspiegeln von lipiden mittels zubereitungen von ob-proteinen
WO1997016550A1 (en) 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
CA2358862A1 (en) 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
AU1406497A (en) 1995-12-06 1997-06-27 Schering Corporation Mutational variants of mammalian ob gene proteins
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO1997026916A1 (en) 1996-01-25 1997-07-31 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US6013009A (en) 1996-03-12 2000-01-11 Karkanen; Kip Michael Walking/running heart rate monitoring system
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
WO1997046585A2 (en) 1996-06-06 1997-12-11 Smithkline Beecham P.L.C. Fragments of leptin (ob protein)
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
EP1001768A1 (en) 1996-08-30 2000-05-24 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
ID21861A (id) 1996-09-20 1999-08-05 Hoechst Ag Penggunaan antagonis leptin untuk pengobatan daya tahan terhadap insulin dalam diabetes tipe ii
AU4582597A (en) 1996-10-11 1998-05-11 Eli Lilly And Company Therapeutic proteins
AU5654998A (en) 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
BR9713755A (pt) 1996-12-20 2000-02-01 Amgen Inc Proteìna, proteìna de fusão, sequência de ácido nucleico, vetor, célula hospedeira procariótica ou eucariótica, processo para produzir uma proteìna, composição farmacêutica, e processo de tratamento de um distúrbio.
US6309360B1 (en) 1997-03-17 2001-10-30 James R. Mault Respiratory calorimeter
AU6569998A (en) * 1997-03-20 1998-10-12 Eli Lilly And Company Obesity protein formulations
AU2951797A (en) 1997-06-06 1998-12-21 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
WO1998056807A1 (en) 1997-06-13 1998-12-17 Gryphon Sciences Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
EP1091440B1 (en) 1998-05-29 2010-06-02 JGC Catalysts and Chemicals Ltd. Method of manufacturing photoelectric cell
WO2000009165A1 (en) 1998-08-10 2000-02-24 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
EP1118001A1 (en) 1998-10-02 2001-07-25 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
AU770712B2 (en) 1999-01-14 2004-02-26 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
CA2359840C (en) 1999-02-12 2012-10-23 Amgen Inc. Glycosylated leptin compositions and related methods
US6475984B2 (en) * 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
TW514510B (en) 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
US6468222B1 (en) 1999-08-02 2002-10-22 Healthetech, Inc. Metabolic calorimeter employing respiratory gas analysis
US6258932B1 (en) 1999-08-09 2001-07-10 Tripep Ab Peptides that block viral infectivity and methods of use thereof
AU782230B2 (en) * 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
US6530886B1 (en) 1999-10-08 2003-03-11 Tanita Corporation Method and apparatus for measuring subcutaneous fat using ultrasonic wave
US7057015B1 (en) * 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
AU1303301A (en) 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Body weight gain inhibitors
JP2001199887A (ja) 1999-11-10 2001-07-24 Takeda Chem Ind Ltd 体重増加抑制剤
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7157564B1 (en) 2000-04-06 2007-01-02 Affymetrix, Inc. Tag nucleic acids and probe arrays
CA2405557C (en) * 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
TW515705B (en) 2000-05-31 2003-01-01 Yamato Scale Co Ltd Visceral fat meter
US6492117B1 (en) 2000-07-12 2002-12-10 Gendaq Limited Zinc finger polypeptides capable of binding DNA quadruplexes
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6475158B1 (en) 2000-10-24 2002-11-05 Korr Medical Technologies, Inc. Calorimetry systems and methods
ES2418954T3 (es) 2001-10-22 2013-08-19 Amgen, Inc. Uso de la leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento
US6899892B2 (en) 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
CN1684990A (zh) 2002-11-01 2005-10-19 株式会社德山 聚合性组合物、其固化体的制造方法以及光学物品
BRPI0414539B8 (pt) * 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
DE602005021858D1 (de) 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
NZ555464A (en) 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
US7898623B2 (en) 2005-07-04 2011-03-01 Semiconductor Energy Laboratory Co., Ltd. Display device, electronic device and method of driving display device
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
EP1976873A2 (en) 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN101400698A (zh) 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
MX2008012666A (es) 2006-03-31 2008-10-13 Amylin Pharmaceuticals Inc Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos.
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CN101113175A (zh) * 2007-04-28 2008-01-30 中国科学院西北高原生物研究所 鼠兔家族瘦素蛋白及其cDNA序列
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2546261A3 (en) 2007-07-31 2013-08-14 Affibody AB New compositions, methods and use
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2195034A2 (en) * 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
KR20100098628A (ko) * 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
EP3103880A1 (en) * 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
DK2389388T3 (en) 2009-01-22 2017-05-01 Keybioscience Ag TREATMENT FOR Obesity
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
EP2576625B1 (en) * 2010-06-04 2018-04-25 TiumBio Co., Ltd. Fusion protein having factor vii activity
CN110437321A (zh) 2010-07-09 2019-11-12 阿菲博迪公司 多肽
CA2812951A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action
CA2813038C (en) 2010-09-28 2021-12-28 Amylin Pharmaceuticals, Llc Highly soluble leptins
WO2013009539A1 (en) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity
US9382304B2 (en) 2011-07-08 2016-07-05 Amylin Pharmaceuticals, Llc Engineered polypeptides having enhanced duration of action with reduced immunogenicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756461A (en) * 1995-06-30 1998-05-26 Eli Lilly And Company Methods for treating diabetes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535659B2 (en) 2010-09-28 2022-12-27 Amryt Pharmaceuticals Inc. Engineered polypeptides having enhanced duration of action
US9879063B2 (en) 2011-07-08 2018-01-30 Aegerion Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Also Published As

Publication number Publication date
JP2014502252A (ja) 2014-01-30
US10087228B2 (en) 2018-10-02
CA3138758A1 (en) 2012-04-19
EP3241558B1 (en) 2021-03-03
ES2641869T3 (es) 2017-11-14
BR122021020041B1 (pt) 2023-03-07
JP6412183B2 (ja) 2018-10-24
US20200362006A1 (en) 2020-11-19
DK3241558T3 (da) 2021-04-26
PT2621519T (pt) 2017-10-04
PL3241558T3 (pl) 2021-08-30
CA2813038C (en) 2021-12-28
CA2813038A1 (en) 2012-04-19
EA024507B1 (ru) 2016-09-30
CN103547590B (zh) 2017-11-28
EP2621515B1 (en) 2017-03-29
US20160083446A1 (en) 2016-03-24
JP6608799B2 (ja) 2019-11-20
BR112013007385A2 (pt) 2021-04-20
WO2012050925A3 (en) 2012-07-05
US11535659B2 (en) 2022-12-27
EP2621515A2 (en) 2013-08-07
MX2013003482A (es) 2013-10-25
JP2013543497A (ja) 2013-12-05
EP2621519B1 (en) 2017-06-28
EP3241558A3 (en) 2018-05-16
WO2012050930A2 (en) 2012-04-19
EP2621515A4 (en) 2014-07-16
BR112013007388B1 (pt) 2022-01-04
WO2012050930A3 (en) 2012-06-14
EA032917B1 (ru) 2019-08-30
EA201390474A1 (ru) 2013-07-30
EP3241558A2 (en) 2017-11-08
DK2621519T3 (en) 2017-10-16
JP6174489B2 (ja) 2017-08-02
US20230115655A1 (en) 2023-04-13
CN103403019A (zh) 2013-11-20
EP2621519A2 (en) 2013-08-07
US20160137709A1 (en) 2016-05-19
WO2012050925A2 (en) 2012-04-19
BR112013007388A2 (pt) 2020-10-06
EP3305315A1 (en) 2018-04-11
CN103547590A (zh) 2014-01-29
MX351128B (es) 2017-10-03
JP2017141232A (ja) 2017-08-17
CN103403019B (zh) 2016-10-12
ES2873253T3 (es) 2021-11-03
DK2621515T3 (en) 2017-07-17
ES2630031T3 (es) 2017-08-17
EA201390497A1 (ru) 2013-09-30
BR112013007385B1 (pt) 2022-07-26
PT2621515T (pt) 2017-07-12
MX2013003472A (es) 2013-10-30
EP2621519A4 (en) 2014-07-09
JP2020033366A (ja) 2020-03-05
CY1119498T1 (el) 2018-03-07
CA2813087A1 (en) 2012-04-19
CY1119023T1 (el) 2018-01-10
MX349054B (es) 2017-07-07
CA2813087C (en) 2020-07-21
US20130274182A1 (en) 2013-10-17
JP2017081939A (ja) 2017-05-18

Similar Documents

Publication Publication Date Title
US10087228B2 (en) Chimeric leptin polypeptide and method of using the same
US9879063B2 (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
WO2013148871A1 (en) Engineered polypeptides
BR122022002534B1 (pt) Polipeptídeo quimérico, seu uso e composição que o compreende

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMYLIN PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ERICKSON, MARY;REEL/FRAME:034987/0240

Effective date: 20120801

Owner name: AEGERION PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AMYLIN PHARMACEUTICALS, LLC;ASTRAZENECA PHARMACEUTICALS LP;REEL/FRAME:034987/0261

Effective date: 20150109

Owner name: ASTRAZENECA PHARMACEUTICALS LP, DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMYLIN PHARMACEUTICALS, LLC;REEL/FRAME:034987/0311

Effective date: 20120919

Owner name: AMYLIN PHARMACEUTICALS, LLC, CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:AMYLIN PHARMACEUTICALS, INC.;REEL/FRAME:035050/0365

Effective date: 20120808

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NOVELION THERAPEUTICS INC., BRITISH COLUMBIA

Free format text: PATENT SECURITY AGREEMENT;ASSIGNOR:AEGERION PHARMACEUTICALS, INC.;REEL/FRAME:045853/0148

Effective date: 20180329

AS Assignment

Owner name: AEGERION PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:NOVELION THERAPEUTICS INC.;REEL/FRAME:050478/0844

Effective date: 20190924